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1.1 Natural Killer cells 
 
Natural Killer cells (NK cells) are the main subset of Innate Lymphoid Cells (ILC) and 
represent the 5-15% of circulating lymphocytes in peripheral blood. NK cells show a high 
potential in tumor surveillance and in defense against viruses (e.g. herpes virus) 1-3. Tissue-
resident NK cells have been found in liver, uterus, and decidua. NK cells have the ability 
to migrate to secondary lymphoid organs (SLOs) and to inflamed tissues where they 
contribute to the first line of defense against various pathogens 2, 4-6. After activation, NK 
cells release chemokines such as MIP-1α/β, CCL5, CXCL1 and cytokines such as IFN-γ, 
TNF- α, GM-CSF, IL-10 which can mediate/increase not only inflammatory responses but 
also contribute to hematopoiesis and activation of granulocytes and monocytes. Moreover, 
NK cells can also interact with dendritic cells controlling their functional maturation, thus 
influencing the adaptive response of Th1 lymphocytes 2, 5. 
Peripheral NK cells are composed of two major subpopulations that can be identified 
through the level of surface expression of CD56 molecule and on the basis of their receptor 
repertoire, functional characteristics and tissue localization. The CD56dim cells is the most 
differentiated and cytotoxic subset that shows a high expression of CD16 and KIR 
inhibitory receptors. They produce lower levels of cytokines as compared to CD56bright and 
reside in the peripheral blood. The CD56bright cells express CD94/NKG2A inhibitory 
receptor well but not KIR, they display low or any expression of CD16 and produce high 
levels of cytokines. They are found mainly in SLO (e.g. lymph nodes). They may represent 




Figure 1. NK cells subsets: CD56dim cytotoxic NK subset express low levels of CD56 



























CD56bright NK subset express high levels of CD56 molecule and is capable to produce IFN-
γ and TNF-α, thus contributing to the activation of monocytes and Th1 response.  
 
 
1.2 Activating receptors/co-receptors and cytolytic activity  
 
NK cells exert cytotoxic activity and cytokines release through a balance between 





Figure 2. Cytotoxic activity of NK cell against tumor cell: A) the target cell cannot 
express ligands for activating receptor and express normal levels of Human Leukocyte 
Antigen class I molecules (HLA-I) blocking NK cell response; B) In the absence of HLA 
class I molecules NK cell cytotoxicity can be inhibited by the lack of expression of 
activating receptor ligands on tumor cells.  C) NK cell activity is exerted by the binding of 
ligand to activating receptor and thanks to the lack of HLA-I molecules on target cell; D) 
the normal expression of both ligands leads to a dynamic balance between NK cell and 
target cell. (Adapted from Leung Wing, 2014) 
 
NK cells can perform their lytic functions through ADCC activation or through the activity 
of Natural Cytotoxicity Receptors (NCR). The recognition by CD16 receptor of IgG-
opsonized cells activates the signal transduction cascade that involves molecules such as 
CD3ζ, FcεRIγ, SyK and ZAP70. This signal cascade terminates with ERK1/2 
phosphorylation that promotes polarization of lytic granules containing Perforin and 
Granzyme A/B and then their exocytosis 13. 
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NCR were identified on NK cells in 1990s. These receptors have the ability to recognize 
specific ligands on virus-infected cells or tumors 14, 15. These Ig-like receptors includes 
NKp30, NKp44 and NKp46; only some ligands of these receptors have been identified 
including BAT3 and B7H6 (NKp30-L), Mixed-Lineage Leukemia-5 MLL5, Sindecan-4, 
Galectin-3 and soluble ligand NID1 (NKp44-L) and CFP and other viral ligands (NKP46-
L). The adapter proteins such as FcεRIγ, CD3ζ and DAP12, specifically related to NCR, 
containing immunoreceptor tyrosin-based activation motifs (ITAM), are responsible for 
the activation signal. NKp44 displays some peculiarities: its cytoplasmic tail contains 
immunoreceptor tyrosine-based inhibition motifs (ITIM) that is capable to inhibit the 
release of cytotoxic agents and IFN-γ 16-18. 
DNAM-1 and NKG2D are other important activating receptors that recognize ligands, 
PVR (CD112), Nectin-2 (CD155) and MICA/B, ULBPs respectively, that are hyper- or de 
novo-expressed only by tumor/stressed cells 10, 19.  
NK cells express also activating co-receptors on their surface such as 2B4 (CD244), NTB-
A (CD352) and NKp80 20-22. The 2B4 receptor belongs to the family of signaling 
lymphocyte activation molecule (SLAM)-related receptors (SRR) and recognizes CD48 
molecule. This receptor shows a long cytoplasmic tail containing tyrosine residues that if 
phosphorylated allow the association of SLAM-associated protein (SAP) and therefore the 
activating signal transduction. The lack of SAP expression triggers an inhibitory signal 
with consequent reduction of cytotoxic activity and production of IFN-γ (condition that 
characterized X-linked lymphoproliferative syndrome, XLP) 21, 23. NTB-A protein is 
similar to 2B4 protein both structurally and functionally, but the activation requires a 
homophile bond with another NTB-A molecule 22.  
Finally, NKp80 receptor, expressed as dimer, recognizes AICL molecule (expressed by 
activating monocytes and tumor cells) and presents a lectin domain in extracellular portion 
and tyrosine-based motifs in the intracellular portion. The interaction with ligand leads to 






                      
Figure 3. Activating receptors, co-receptor and their ligands: NKp46, NKp30 and NKp44 
(NCR), containing ITAM in the intra-cytoplasmic portion, are associated with ζ/γ signaling 
protein, which is responsible to activating signal. NKG2D is a C-type lectin receptor that 
presents YxxM intra-cytoplasmic PI3K-binding motifs and is associated to DAP10 adaptor 
protein for signal transduction. DNAM-1, 2B4 and NTB-A have IgV and IgC extracellular 
domains. NTB-A and 2B4 translate the activating signal thank to the involvement of SAP 
and SHP-1 proteins. NKp80 have two C-type lectin extracellular domains and 




1.3 Inhibitory receptors and their HLA-I ligands 
The inhibitory counterpart of NK cell receptors is represented by specific molecules 
including killer Ig-like receptors (KIR), C-type lectin receptor CD94/NKG2a and 
Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR1) 14, 24, 
25. The receptor CD94/NKG2a recognizes the expression of HLA-E (non-classical HLA-I 
molecule) on cells by binding peptides derived from leader sequence of classical HLA-I 
molecules 11, 14, 24, 26. The gene of NKG2a is located on chromosome 12.  
It exists an activating counterpart, named CD94/NKG2c that recognizes the same 
molecules and it is associated with ITAM motifs and DAP12 adaptive protein for 
activating signal transduction. It has been observed that HCMV infections promote the 
oligoclonal expansion of mature NK cells expressing high levels of NKG2c receptor 27, 28. 
LIR1 inhibitory receptor can contain 2 or 4 Ig domains and 2 to 4 ITIM; its gene resides on 
chromosome 19q13.4. This receptor binds HLA-I molecules and non-classical HLA-I 
molecules leading to an inhibitory signal 24.  
KIR receptors are clonally distributed, their genes (family of 13 genes) are located in 
Leukocytes Receptor Complex (LRC) on chromosome 19q13.4 and are inherited as 
haplotypes. There are two KIR haplotypes: haplotype A is characterized by KIR2DL1, 
KIR2DL3, KIR3DL1, KIR3DL2, KIR2DL4 genes encoding inhibitory isoforms, 
KIR2DS4 encoding activating isoform and two pseudo-genes KIR2DP1 and KIR3DP; 
haplotype B include KIR2DL2, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, 
KIR2DS3, KIR2DS5 and KIR3DS1 genes. Inhibitory KIR (iKIR) are identified by 2 
(KIR2D) or 3 (KIR3D) Ig-like domains in their extracellular portion and by a short or long 
intra-cytoplasmic chain. The long cytoplasmic chains (KIR2DL and KIR3DL) are 
characteristic of the inhibitory isoforms and contain ITIM, which recruit protein tyrosine 
phosphatases that mediate inhibitory function 25, 29. The activating isoforms (aKIR) are 
characterized by short cytoplasmic chains (KIR2DS and KIR3DS) containing ITAM 
associated to signaling adaptor protein KARAP/DAP12, which are implicated in activating 
signal transduction. It was observed that KIR2DS4 activating receptor is present only in 
some individuals and may also positively contribute to the anti-leukemia activity 29, 30. 
Recently, Dumas PY et al suggested that KIR2DL5B genotype of CML patients has a role 
in the control of minimal residual disease (MRD) in patients with CML relapse 31.   
HLA-I ligands are represented by HLA-A, HLA-B and HLA-C and their genes reside on 
chromosome 6 (except β2-microglobulin located on chromosome 15) 29. The acquisition of 
KIR inhibitory receptors from NK cells undergoing differentiation from CD34 HSC after 
hematopoietic Stem Cell Transplantation (HSCT) may have an important role against 
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leukemia stem cells (LSC), also called minimal residual disease (MRD) 29, 32. After 4 
weeks, donor NK cells are completely functional and can express specific KIR receptors 
for donor HLA-I molecules and not recipient (mismatch) 29, 33. This NK cells are defined 
“alloreactive NK cells” and have high lysis efficiency against any residual leukemic blasts 
34-36. The NK cells alloreactivity was first described more than 20 years ago by Moretta A 
et al 29, 32, 37.  
During NK cells development, after interaction between KIR receptors and HLA-I “self” 
ligands, NK cells become educated/licensed to exercise alloreactivity against allogeneic 
targets that do not express HLA-I “self” ligands 29. 
 
 
                  
                                             
Figure 4.  Killer Ig-like inhibitory and activating receptors consist of Ig domains: KIR2D 
encodes 2 domains with D1 and D2 conformation or D0 and D2 conformation; KIR3D 
encodes 3 domains with D0, D1 and D2 conformation. KIR2DL1, KIR2DL2/L3, 
KIR2DL5, KIR3DL1 and KIR3DL3 contain 2 ITIMs in intra-cytoplasmic tail. Differently 
from other iKIR, in addition to the presence of single ITIM, KIR2DL4 contains a charged 
residue in its trans-membrane region and 4 ITAM in associated protein FcεRγ, suggesting 
a possible activating role. KIR2DL4 is the only isoform that bind non-classical HLA-G 
molecule.  (Adapted from Pende D et al, 2019). 
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1.4 Origin and development of ILC/NK cell  
 
NK cell development occurs primarily in the bone marrow (BM) and in other sites such as 
thymus and lymph nodes and requires the expression of NFIL3, Tbx21, RUNX1, BLIMP1, 
EOMES, ETS-1, GATA3, TOX1 and ID2 transcription factors (TF) 8, 38-40. This process is 
characterized by the sequential acquisition of surface markers (including CD161, CD56, 
CD94/NKG2a, LFA-1, CD16, KIRs and CD57) and functional capabilities 39, 41, 42. 
Another important NK maturation marker is NKp80 that discriminates between stage 4a 
represented by IL-22 producing RORγt+AHR+ILC3 and stage 4b characterized by IFN-γ 
producing Tbet+EOMES+ NK cells during development in secondary lymphoid tissues 
(SLTs) 20.  
 
 
Figure 5: Six-stages NK cell development model: the specific markers that identify 
different steps are highlighted in red. Stage 1 and stage 2 characterized by CD34+ multi-
potent cells that can give rise to dendritic cells (DC), T cells and NK cells. In particular, 
Stage 2b is an important step represented by IL-15 receptor (IL-15R) β chain (CD122) and 
IL-7 receptor (IL-7R) CD127 expression on NK cells precursors.	The interaction between 
IL-15R and IL-7R and their ligands is essential for differentiation of cytolytic NK cells and 
homeostasis respectively. Stage 4 is divided into stage 4a and stage 4b depending on 
NKp80 surface expression and TF. Stage 3 and Stage 4a are represented by CD161+/-
CD56-CD117+ NK cells precursors and NCR expressing ILC3.  (Adapted from Abel AM 
et al 2018) 
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NK cells have been recently included in a larger family of innate lymphocytes, called 
Innate Lymphoid cells (ILC) 43. All of them derive from a common DNA-binding protein 
inhibitor (ID2)-positive hematopoietic precursor and both express IL-2Rγ (common 
receptor for IL-2, IL-7, IL-15 and IL-21) 39, 40, 44. The ILC classification and nomenclature 
was defined in 2013 by Spits et al. ILC are divided into three groups according to 
phenotypic and functions properties 45. NK cells are the only cytotoxic subset while other 
ILCs are characterized by the ability to produce several different cytokines. With the 
exception of NK cells, ILCs display a preferential tissue distribution: they are mainly 
found in gut, lungs, decidua and skin where they have a protection role in skin 
inflammations. ILC1 group is characterized by t-bet TF expression, production of Th1- 
associated cytokine IFN-γ; it resides in gut and has a defense role against intracellular 
pathogens and protozoa 45. ILC2 group produces Th2-related cytokines such as IL-5 and 
IL-13 and for its development depends on GATA3, RORα and BCL11B TF; is involved in 
defense against parasites and in allergic disease. Finally, ILC3 group requires AHR and 
RORγt TF, may express NKp44 receptor and are activated by IL-23 and IL-1β to produce 
IL-17 and IL-22 Th17-related cytokines; primarily defined lymphoid tissue inducer (LTi) 
cells, seem to be involved in lymph node organogenesis during fetal life and in maintaining 
the integrity of intestinal epithelium during adult life, where they contribute to host defense 
against extracellular pathogens 43, 45-49. In recent years, it has been observed a positive	role 
of ILC3 during intestinal inflammation. However, ILC3 may also increase intestinal 
inflammation converting them into IFN-γ-producing ILC1 upon IL-12 stimulation 50, 51. 
The constantly activation of ILC3 and thus, the high and sustained production of IL-17 and 
IL-22, have been suggested to promote colorectal tumor growth and metastasis 52, 53.  
Several mouse and human in vitro and in vivo studies have shown that ILCs can convert in 
other subsets in the presence of specific cytokines 54. In particular, the plasticity of murine 
RORγt+ILC3 is well been demonstrated in vivo; murine ILC3s are divided in two majors’ 
subsets, LTi cells and NCR+ILC3 (and their NCR-ILC3 precursors). NCR+ILC3 are 
characterized by NKp46 surface expression, lack of CCR6 chemokines receptor expression 
and IL-22 secretion. LTi cells instead are specialized in IL-17 production. CCR6-
NKp46+ILC3 can convert to ILC1 responding to IL-12 (ex ILC3) and produce IFN-γ when 
stimulated with IL-2 or IL-15 54, 55. A study of Bernink JH et al shows that the reversion of 
ILC1 to ILC3 can be supported by IL-23 but the molecular process of this conversion 
remains unknown.	Recent studies revealed that human ILC3, isolated from pediatric tonsils 
and from humanized mouse tissues could differentiate in NK cells stage 4 51. 
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Figure 6. Plasticity of ILCs: IL-12 stimulates the phenotype and functional conversion of 
ILC3 to ILC1-like (“ex-ILC3”) while IL-23 and IL-1β reverse to RORγt+-ILC3. ILC2 can 
be converted into “ex-ILC2” thanks to IL-12 and IL-33 stimulations. IL-4 stimulates the 
conversion of “ex-ILC2” into GATA3+-ILC2. NK cells respond to TGF-β acquiring 
CD49a and/or CD49b molecules to become ILC1 and intra-epithelial ILC1 (ILC1int). 






Figure 7. ILC and NK cells derived from Common Lymphoid Precursor (CLP) that 
differentiates in Common Innate Lymphoid Progenitor (CILP). CILP can give rise both to 
ILC/LTi precursor CHILP and to the NK cell precursor (NKP) through the specific TF. 






Figure 8. ILC and NK cells immune functions: different stimuli activate NK cells and 
ILCs which through the release of cytokines and/or lytic granules that can mediate immune 
response.  (From Vivier E et al 2018) 
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1.5 In vitro model of ILC3/NK differentiation 
 
ILC3/NK cells develop from umbilical cord blood (UCB)-derived CD34+ cells thanks to 
an appropriate stimulation that involves some cytokines such as stem cell factor (SCF), 
FMS-like tyrosine kinase 3 Ligand (FLT3-L), IL-7, IL-15 and IL-2139. This in vitro model 
can also give rise to CD33+CD14+/- myeloid-monocytes cells and provides for five 
differentiation stages based on phenotypic and functional characteristics: stage I 
CD34+CD117-CD94/NKG2a-CD56-, Stage II CD34+CD117+CD161+/-CD94/NKG2a-
CD56-, Stage III CD34-CD117+CD161+LFA-1-CD94/NKG2a-CD56+ (immature NK cells), 
Stage IV CD34-CD117-LFA-1+CD94/NKG2a+CD56brightCD16dim able to produce IFN-γ 
and Stage V CD34-CD117-CD94/NKG2a+/-CD56dimCD16brightKIR+/- EOMES+ which 
instead performs cytotoxic activity through release of cytolytic granules containing 
perforin and granzyme A/B. From the NK stage III can derive both CD34-CD117+ LFA-1-
CD94/NKG2a-CD56+RORγt-ILC3 and NK stage IV 47, 56. Lymphocyte function-associated 
antigen 1 (LFA-1 or CD11a) is an adhesion molecule belonging to the integrin 
superfamily. The interaction between LFA-1 molecule and their ligands such as 
intercellular adhesion molecule 1 (ICAM-1) and ICAM-2 leads to immunological synapse 




Figure 9.  Five steps represent NK/ILC3 in vitro differentiation model. CD34+ precursors 
isolated by UCB are cultured with SCF, FLT3-L, IL-7, IL-15 and IL-21. After 7-20 days of 
culture (Stage 3) can obtained both immature NK cells and ILC3. The cytokines 
production and cytolytic activity increase according to NK cell maturation. After 25-30 
days of culture are obtained fully functional mature NK cells (CD56+/-CD94/NKG2a+/-









1.6 NK cells immunotherapy and Molecular Targeted Therapy 
 
NK cells contribute to the immune response against hematological malignancies such as 
chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) through NCR-mediated cytotoxic activity and, indirectly, 
by contributing to the activation of T-CD8 cells and of macrophage responses 58.  
The improved cytotoxic activity of NK cells correlates with better prognosis and arrested 
disease progression. Unfortunately, leukemic blasts can compromise autologous NK cells 
functions and thus elude the immune-surveillance of the immune system through several 
tumor escape mechanisms such as: the modulation of NCR/NKG2D ligands, the increase 
of HLA-I molecules as well as the release of soluble factors 59-62. 
The allogeneic-hematopoietic stem cell transplantation (allogeneic-HSCT) is a high-risk 
treatment for the patients but very effective in eradicating leukemia. Heterologous NK 
cells derived from HSCT can prevent relapses but not all patients are eligible for this 
treatment and the effect maybe only transitory, requiring therapy maintenance. For this 
reason, in the last few years, alloreactive-NK mediated immunotherapy protocols and 
engineered NK cells (chimeric antigen receptors, CAR) have been designed (see Figure 





Figure 10.  NK cell immunotherapy: a) autologous NK cell are activated and expanded in 
vitro with IL-2, IL-15, IL-21 and IL-18 cytokines and infused into the patient; b) 
allogeneic NK cells are isolated from CBMC of healthy donor and then are selected. After 
NK cells activation and proliferation, donor NK cells are infused into the receiving patient; 
c) patient/donor NK cells or NK cell line (NK92) are engineered with Chimeric Antigen 
Receptor (CAR) specific for tumor antigens. (Adapted from Guillerey C et al 2016) 
 
Otherwise, the therapy of choice for CML and ALL is still molecular targeting therapy, 
which has improved the prognosis of patients 66, 67. Drugs such as selective Tyrosine 
Kinase Inhibitors (TKIs) have been introduce 20 years ago and had a key role in improving 
the overall survival of CML patients. However, TKIs cannot be considered as a curative, 
because high percentages (50-60%) of patients develop resistance or lack of complete 
molecular remission 66, 68-70.  
CML is a myeloproliferative disease that originates from hematopoietic stem cells (HSCs) 
and is represented by leukocytosis and splenomegaly. CML is characterized by increased 
proliferation of the granulocytic cell line without the loss of their capacity to differentiate. 
Consequently, the peripheral blood cell profile shows an increased number of granulocytes 
and their immature precursors, including occasional blast cells. CML accounts for 20% of 
all leukemias affecting adults.	CML progresses in two phases: a chronic phase (CP), an 
asymptomatic phase characterized by abnormal proliferation of granulocytes and their 
precursors in BM and PB involving 90% of patients at diagnosis, and an accelerated phase 
(AP) or blast crisis, represented by increase numbers of immature leukocytes, similarly to 
AML, in which symptoms like weight loss, fever, enlarged spleen and anemia begin to 
appear. In almost all CML patients have been identified the Philadelphia chromosome (Ph) 
and its corresponding protein BCR-ABL, constitutively activated71. 
BCR-ABL tyrosine kinases are the main target of TKIs, which derive from chimeric gene 
BCR-ABL, originating from translocation between terminal fragment of chromosome 9 
and chromosome 22, that generates the Ph. These aberrant proteins kinases, named p210 
(CML and AML associated) and p190 (mainly correlated to ALL), are able to 
phosphorylate different substrates favoring the proliferation of blasts, reducing apoptosis 
and modifying adhesion mechanisms and response to regulation factors 72-76. 
Imatinib mesylate (STI571, Gleevec, Glivec) was the progenitor drug used in first-line 
treatment of CML-Ph+, ALL-Ph+ and gastrointestinal stromal tumors (GISTs) both in adult 
and pediatric patients. The targets of Imatinib are BCR-ABL tyrosine-kinase, c-KIT (Stem 
Cell Factor Receptor), PDGF-R (Platelet-Derived Growth Factor Receptor) and VEGF-R 
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(Vascular Endothelial Growth Factor Receptor). This therapy presents a lot of side effects; 
the most common are neutropenia, thrombocytopenia and anemia 77. Different mechanisms 
of resistance have been observed, especially in the advanced stage of disease, these 
include: increases of BCR-ABL kinase through the BCR-ABL gene amplification/mutation 
(e.g. T315I point mutation), excessive binding of Imatinib to plasmatic proteins, 
intracellular decrease of drugs due to high expression of Multidrug-resistant P-
glycoprotein (or p-glycoprotein 1 coded by MDR1 gene) and high expression of proto-
oncogene tyrosine-proteins kinase (Src) 78.  
These drug resistances led to the development of second generation TKI that are more 
potent and selective. Nilotinib (AMN107, Tasigna), that is structurally similar to Imatinib 
and specific for the same targets, is mainly indicated for the treatment of CML-Ph+ in adult 
patients. Dasatinib (Sprycel, BMS-354825) is a BCR-ABL inhibitor that is active on some 
Src-kinases (Lck and Hck) and also used for the treatment of pediatric patients suffering 
from LLA-Ph+. Moreover, Dasatinib is the only drug of TKI family that is capable of 
crossing the blood-brain barrier (BBB) and acts on brain metastases caused by LLA-Ph+ 79. 
These second generation of inhibitors cannot overcome the resistance due to the presence 
of T315I point mutation of BCR-ABL. Therefore, new drugs have been developed such as 
Ponatinib, a third generation TKI approved for the treatment of CML patients that are 
resistant to, or intolerant to other TKI 67, 72, 77, 80.  
The role of TKI therapy in the early-stage of disease control is been demonstrated. On the 
other hand, the effect of TKI on the outcomes of HSCT in CML patients is under 
evaluation. A retrospective analysis of 2016 shows that maintenance TKI therapy after 
HSCT might reduce the incidence of relapse and improve outcomes of high-risk Ph+ 
leukemia patients 81.  
Clinical evidences have shown that 50% of patients in sustained Deep Molecular 
Remission (DMR) may interrupt their TKI treatment without clinical relapse (Treatment 
Free Remission, TFR) 82. Several experimental and clinical observations supported the 
notion the TKI may successfully cure leukemia only in those patients in which it is 
possible to observe the restoration of antitumor immune response 83-85. In this context, NK 
cells seem to play an important role in the control of the CML residual disease and this NK 
cell-mediated immune response may to be correlated with a better clinical outcome 83, 86.   
It was observed that in CML patients treated with Imatinib, the increase of cytotoxic 
mature NK cells was associated with the successful therapy discontinuation 87. Moreover, 
it has been reported that Dasatinib induces a rapid CD56+CD57+ NK cells mobilization in 
PB and BM of CML patients 88-90. Dasatinib-treated patients that interrupted therapy and 
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remained in deep molecular response (DMR) for more than 1 year displayed high numbers 
of circulating NK cells and CTL 91. Of note, one of the side effects of Dasatinib treatment 
is the onset of pleural effusion (PE): the mechanism of Dasatinib-related pleural effusion is 
still unclear but it has been observed a correlation Dasatinib-mediated lymphocytosis, PE 
and better clinical outcome 77, 92.  
Despite these data, still half of patients relapse after therapy discontinuation: the presence 
of resistant LSCs (MRD) may be responsible of these events. There are many BCR-ABL 
independent mechanisms of resistance.  LSCs are characterized by low 
activation/proliferation (state of quiescence), overexpression of p-glycoprotein 1, TGF- α/β 
, TNF-α, Jak-STAT and reside in BM 72, 78, 93. Other mechanisms involve signaling 
pathways such as RAF/MEK/ERK or epigenetic deregulation. Thus, it would be important 
to analyze the BM microenvironment where leukemic stem cells reside, since it could have 
a crucial role in promoting disease progression: the surrounding stromal cells such as 
mesenchymal stromal cell (MSCs) contribute to genesis of leukemic clone and to 
protection of LSCs from TKIs effects 93, 94. At the same time, BM microenvironment may 
interfere with NK cell differentiation, maturation and survival, and therefore impair the 





Figure 1. TKI approved for CML: Imatinib, Dasatinib, Nilotinib are approved both for use 
in the first line and in the accelerated phase. Ponatinib is not approved in first line but is 





Figure 12. The most common TKI side effects are anemia, neutropenia and 
thrombocytopenia. Other common side effects are fatigue, rash, headache and nausea. 
Pleural effusion is more frequently side effect in Dasatinib-treated patients.  (Adapted from 





2. AIMS OF THE PROJECT	
 
AIM 1) The first aim of this project was to verify whether the TKI drugs interfere with 
ILC/NK cells differentiation and modify the phenotype, the production of cytokines and 
the cytolytic activity of ILC/NK cells. Our goal was to understand whether such 
compounds may affect the generation of potential antileukemic activity of NK/ILC cells 
undergoing differentiation in the PB and BM of CML patients. Our results have been 
published in 2018 (Damele L et al 2018). 
Damele, L., Montaldo, E., Moretta, L., Vitale, C., Mingari, M. C. Effect of Tyrosin 
Kinase Inhibitors on NK Cell and ILC3 development and function. Front. Immunol. 9, 
2433. doi: 10.3389/fimmu.2018.02433 (please see the attached file). 
 
AIM 2) The second aim of my project was to characterize the lymphocyte and myelo-
monocyte populations in PB and BM of patients affected by CML before and during 
treatment with TKI. In particular, I've been focused on the characterization of NK cell and 





















Tyrosine kinase inhibitors (TKI) sharply improved the prognosis of Chronic Myeloid 
Leukemia (CML) and of Philadelphia+ Acute Lymphoblastic Leukemia (Ph+ALL) patients. 
However, TKI are not curative because of the development of resistance and lack of 
complete molecular remission in the majority of patients 66-70, 72. Clinical evidences would 
support the notion that patient’s immune system may play a key role in preventing relapses 
82, 83. In recent years, it was observed that NK cell immune response seems to correlate 
with a positive clinical outcome 83, 86.  In particular, increased proportions of terminally 
differentiated CD56+CD16+CD57+ NK cells have been reported to be associated with 
successful Imatinib therapy discontinuation (TFR) or with a DMR in Dasatinib-treated 
patients. Thus, it would be important to study whether any TKI have an effect on 
circulating mature NK cells and on their development by using in vitro models that could 
allow the identification of possible molecular mechanism(s) by which continuous exposure 
to TKI may influence NK cell development and repertoire 90, 92, 96-98.  To this end, CD34+ 
hematopoietic stem cells (HSC) were cultured in the absence or in the presence of 
Imatinib, Nilotinib, or Dasatinib at the plasma peak concentration (to reproduce 
concentration present in PB and BM of TKI-treated patients), or with DMSO as a vehicle 
control 56, 95. Between day 15 and 27 of culture, cells were counted and repeatedly 
analyzed by flow-cytometry for NK-specific surface markers, cytokines production, 
cytolytic activity and transcription factors. 
The results show that all compounds exert an inhibitory effect on CD56+ cell recovery. In 
addition, Dasatinib sharply skewed the repertoire of available CD56+ cells towards 
CD56+CD117+CD94/NKG2a-RORγt+ IL-22-producing ILC3 cell population, leading to 
an impaired recovery of CD56+CD117-CD16+CD94/NKG2a+NKG2D+DNAM1+EOMES+ 
mature cytotoxic NK cells. Interestingly, the few NK cells undergoing differentiation in 
the presence of Dasatinib, displayed the capacity to express high percentages of IFN-γ; we 
also detected a slight increase of IL-8/IFN-γ-producing ILC3. Of note, ILC3 play a crucial 
role in intestinal inflammation due to their ability to become IFN-γ-producing ILC1 (“ex-
ILC3”) upon IL-12 stimulation 50-53, 55. Different from IFN-γ 77, 99, production, both 
Nilotinib and Dasatinib reduced the cytolytic activity of NK cells undergone in vitro 
differentiation against the leukemia cell line K562.  
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Further, analysis performed at early time cultures intervals revealed an increase of 
CD56+CD117+CD127+ cells that might represent ILC3 precursors supporting the 
hypothesis that Dasatinib may skew ILC commitment towards ILC3. 
It has been reported that Dasatinib, but not Imatinib and Nilotinib, exerts an inhibitory 
effect on the family of Src kinases: thus, it was possible that the Dasatinib -mediated effect 
on ILC differentiation, may reflect an inhibitory effect on Src kinases occurring at the level 
of cell precursors 79, 100. To study this, CD34+ cells were cultured with KX2-391 Src- 
kinase inhibitor used at different concentrations. After 25 days of culture, the cells were 
collected and analyzed for phenotypic and functional maturation markers. The results 
showed that the low concentrations of KX2-391 (i.e. 5 µM) did not inhibit CD56+ cells 
recovery. However, similarly to the Dasatinib-mediated effect, the use of this inhibitor 
increased the expression of CD117 and RORγt TF and decreased the expression of 
CD94/NKG2a and EOMES TF. Moreover, the CD56+ cells undergoing differentiation in 
the presence of KX2-391 displayed a low cytotoxic activity similar to Dasatinib-treated 
cells.  
Previous studies on in vitro human ILC differentiation have shown that also the cytokines 
used in this model of NK cell differentiation may play a role in the ILC commitment.  In 
particular, SCF has a key role in ILC3 development in the presence of IL-7 or IL-15, while 
IL-15 and IL-7 alone, or in combination with other cytokines such as IL-1β, skew 
differentiation towards CD56+ NK cells 47, 95, 100, 101. In this context, it has been described 
that IL-7 is required for ILC3 homeostasis and development within the lymph nodes 102. 
IL-7 exploits both STAT3 and STAT5 transduction pathway; IL-15 preferentially uses 
STAT5 signaling protein while the interaction between SCF and c-KIT (CD117) involves 
STAT3 protein. Of note, it has been observed by Konig H et al. that Dasatinib, transiently 
inhibits STAT3 phosphorylation, while induced a durable inhibition of STAT5 signaling 
pathways in CD34+ cells isolated from CML patients at diagnosis 79. This durable 
inhibition seems to be due to the inhibitory effects mediated by Dasatinib on Src-kinase 
activation pathway that, in turn, modulate STAT5 phosphorylation 100, 103. Our analyses of 
STAT3/STAT5 phosphorylation status in Dasatinib–stimulated CD34+HSC revealed a 
more durable reduction of pSTAT5+ cells as compared to pSTAT3+ cells during the first 
days of culture. These results, according to the early expression of CD117 and CD127 
observed on Dasatinib-treated precursors, may support the hypothesis that the the SCF/c-
KIT and IL-7/CD127-mediated STAT3 transduction pathway, may overcome Dasatinib-
mediated inhibition and favor the preferential ILC3 precursors survival and maturation.  
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It has been observed that Dasatinib may induce lymphocyte's mobilization that may lead to 
systemic inflammation and side effects such as pleural effusion and colitis 77, 90, 92. This 
could be associated with the increased of NK and IFN-γ or IL-22 producing ILC3/ILC1. 
On the other hand, our data are in contrast with in vivo data that documented the presence 
of cytotoxic NK cells in vivo in the PB and the BM of Dasatinib-treated patients, maybe 
because to a high stability of the drug in our cell cultures. It has been suggested that the 
numbers of circulating cytotoxic NK cells and cytotoxic T lymphocytes (CTL) were 
significantly higher in DMR patients 88, 89. The high degree of heterogeneity of analyzed 
cases may contribute to the variability of responses: patients treated with different TKIs, 
and the immune system status (e.g. viral activation) may influence immune cell repertoire 
and function and then the clinical outcome of CML-patient. 
Taken together, our studies reveal a possible mechanism by which Dasatinib may interfere 
with the proliferation and maturation of fully competent NK cells, i.e.by targeting 
signaling pathways required for differentiation and survival of NK cells but not of ILC3.  
Finally, our study could identify new tools to design individualized timing and dosing of 
Dasatinib application, in order to obtain good responses without impairment of NK cell-
based immunotherapeutic interventions.  
 
Ref: Damele, L., Montaldo, E., Moretta, L., Vitale, C., Mingari, M. C. Effect of Tyrosin 
Kinase Inhibitors on NK Cell and ILC3 development and function. Front. Immunol. 9, 














As discussed previously, in the last years, several papers reported data on the NK cell 
repertoire in CML patients undergoing TKI therapy. Generally, these papers support a 
correlation between the achievement of a durable DMR, also in the case of TKI therapy 
suspension, with the presence of mature CD56+CD57+KIR+NKG2a- cytotoxic NK cells in 
patients' peripheral blood. However, in view of these interesting findings, more detailed 
analysis could further contribute to identify patients potentially eligible for a safe therapy 
suspension. In particular, patient's longitudinal analysis and comparison between patient's 
PB- and BM-derived NK cells could offer new insights in the potential ability of these 
cells to eradicate residual leukemic disease.   
In view of the in vitro data on NK /ILC differentiation in the presence of TKI drugs that 
we previous reported, we decided to start a longitudinal follow up of CML patients 
undergoing TKI therapy at UO Hematology 1 and Hematological clinic of San Martino 
Polyclinic Hospital in Genoa. Our plan is to perform deep analyses that should include 
characterization of NK and T cell, of myeloid cell compartment, and of soluble plasma-
derived factors. Below, we present very preliminary data regarding NK cells obtained in 






4.2.1 Analyses of PB NK cells in patients undergoing TKI therapy 
The lymphoid cell repertoire of five patients affected by CML was analyzed at diagnosis 
and at different time intervals during TKI therapy (1-3-6-12 months). Below, we present 
data regarding four patients undergoing Nilotinib therapy and one patient undergoing 
Dasatinib treatment. For further patients details please see Table 1 and Materials and 
Methods section.   
We focused our studies on PB NK cell repertoire: mononucleated cells were freshly 
isolated from PB and subjected to flow cytometric analyses for the identification of the 
specific surface markers (Figure 13). The results indicated that Nilotinib patients have 
lower CD3+ cell percentages at diagnosis as compared to other time intervals during 
therapy, while the percentages of CD56+ cells remain quite stable in time (Figure 13B). 
The only patient undergoing Dasatinib treatment showed a decrease of CD3-CD56+ NK 
cell percentages during the first month of therapy, while the percentages of CD3+ cells 
increased during therapy.  Among CD56+ cell subsets, the percentages of CD56bright, 
including CD117+ cells, were more represented at diagnosis while decreased during 
therapy, in particular in Nilotinib-treated patients. On the other hand, the percentages of 
terminally differentiated CD56+CD57+ NK cells increased during both Nilotinib and 
Dasatinib therapy treatment. In particular, Nilotinib-treated patients displayed higher 
percentages of CD56+CD57+ cells as compared to the Dasatinib-treated patient (Figure 
13C). The further analyses indicated that both in the presence of Dasatinib and Nilotinib 
there was a high variability of CD56+ NK cell percentages expressing activating receptors 
during the different time intervals. Of note, despite the high variability of NK cell 
percentages expressing NKp46 and NKG2D receptors, we could observed a progressive 
increase of NKp46 and of NKG2D surface MFI on CD56+ cells in Nilotinib-treated 
patients (Figure 14A, Figure 15). On the other hand, Dasatinib-treated patient displayed 
an increase of CD56+NKG2D+ cells during therapy as compared to diagnosis, but the MFI 
greatly varied among the different time intervals. In the same patient, NKp30+ NK cells 
decreased after 6 months of therapy, while the receptor MFI maintained higher levels as 
compared to diagnosis. Finally, DNAM-1+ cells could be always observed at different time 
intervals both in Nilotinib and Dasatinib patients however, in Nilotinib patients’ receptor 
MFI rapidly increased during therapy, while in Dasatinib patient receptor MFI increased 
only after one year of therapy (Figure 14A, Figure 15). The detection of NK inhibitory 
receptors revealed that the percentages of CD56+CD94/NKG2a+ were more represented in 
Dasatinib-treated patient as compared to Nilotinib-treated patients. In particular, the patient 
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displayed high percentages of CD56+CD94/NKG2a+ that decreased only after 12 months 
from the beginning of the therapy. Of note, we always detect high percentages of 
CD94/NKG2c+ NK cells in Nilotinib patients at all time intervals analyzed. We know 
analyzed in Nilotinib patients. In this context we know that none of these patients suffered 
of CMV reactivation or infection during therapy but we could obtain data on CMV 
positive serology at diagnosis for only 2/4 of the Nilotinib patients (Figure 14B).  
In order to characterize the functional features of NK cells, we evaluated cytokine 
production and the CD56+ cells cytotoxic potential by the CD107a degranulation assay. 
Figure 14C, shows CD107a+ NK cell percentages detectable after 3 hours of incubation 
with the HLA-class I- K562 leukemic cell line. Both Nilotinib-treated patients and 
Dasatinib-treated patient displayed an increase of CD107a+ cells during therapy as 
compared to the diagnosis. However, our preliminary data indicated that Nilotinib-treated 
patients experienced a decrease of CD107a+ cells at 12 months while, at the same time 
interval, Dasatinib-treated patient still displayed a 40% of CD107a+ NK cells upon 
incubation with K562 cells. As shown in Figure 14C, unfortunately we could not perform 
CD107+ analysis on Dasatinib patient at diagnosis thus, the histograms represent data 
starting from 1 month after beginning of the therapy. 
To test intra-cytoplasmic cytokines production, patient-derived PB lymphocytes were 
overnight stimulated with IL-12, IL-15 and IL-18 and analyzed for the expression of IFN-γ 
by flow cytometer analysis. The results revealed that CD56+ cells derived both from 
Nilotinib- and Dasatinib-treated patients could express similar percentages of CD56+IFN-
γ+ cells and these amounts were also comparable to those observed in healthy controls 
(Figure 14D). As shown in Figure 14D, unfortunately we could not perform cytokine 
expression analysis on Dasatinib patient at diagnosis thus, the histograms represent data 
starting from 1 month after beginning of the therapy.  
Our in vitro data on NK cell differentiation would suggest that Dasatinib treatment could 
favor the development of ILC3 that displayed higher percentages of IL-22+-producing 
CD56+ cells as compared to controls. Thus, we verified the ability of lymphocytes isolated 
from TKI treated patients to produce IL-22. To this end, lymphocytes were stimulated also 
with IL-1β, IL-7, and IL-23 cytokines, known for their ability to induce IL-22 production 
by innate lymphoid cells. Again, we could not perform such analysis in Dasatinib-treated 
patient at diagnosis. Our results would suggest that Dasatinib-treated patient displayed 
higher percentages of CD56+ cells able to express detectable amounts of IL-22 as 
compared to Nilotinib patients (Figure 14D). 
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4.2.2 Dasatinib-treated patient displayed detectable amounts of ILC3 RORγt+IL-22 
producing cells in the peripheral blood at early time intervals following therapy 
beginning. 
 
In view of our in vitro data on NK/ILC development in the presence of TKI, we also 
evaluated the presence of ILC3 in the PB of our patients.  To this end, PB ILC cell 
percentages (CD45+CD3-CD14-CD19-CD127+) and the expression of ILC3 lineage-related 
RORγt TF and IL-22 cytokine production were evaluated by flow cytometry (Figure 16A). 
The Figure 16B shows that very low percentages of ILCs were detectable in patients PB. 
Interestingly, our preliminary data revealed that Dasatinib-treated patient express little 
higher percentages of ILCs at 1 and 3 months as compared to Nilotinib-treated patients. At 
the same time intervals, Dasatinib-treated patient displayed higher percentages of LIN-
CD127+CD117+RORγt+ cells as compared to Nilotinib patients and to healthy controls. 
Functional analyses revealed that RORγt TF expression paralleled the expression of IL-
22, meaning that, Dasatinib-treated patient had higher percentages of LIN-
CD127+CD117+IL-22+ cells as compared to Nilotinib patients and to healthy controls 
(Figure 16C).  
 
4.2.3 BM-derived NK cells in CML patients at diagnosis are enriched in CD56bright 
CD16- cells and display lower levels of activating receptors and lower ability to 
express IFN-γ .  
 
We could also analyze the medullary blood of 3/4 Nilotinib-treated patients that we 
received at diagnosis and after three months of therapy. The Figure 17A shows that the 
percentages of CD3+ and CD56+ cells in PB were higher than in BM at diagnosis. At 
diagnosis, in the BM the percentages of CD56brigh cells detectable in BM, including 
CD117+cells, slightly overcome CD56dim CD56+CD57+ cells, which, on the other hand, 
represented the majority of NK cells in the PB (Figure 17B).  Analyses of NK cell 
receptor expression revealed that in the BM the median percentages of CD56+cells 
expressing NKp30, NKG2D and DNAM-1 were lower than those detected in the PB. Of 
note, we could also observe that NKp30 MFI decreased after 3 months, in particular in the 
BM (Figure 18A, Figure 19).  We also compared the expression of inhibitory receptors on 
CD56+ NK cells in PB and in BM. Data are limited, however, it seems there could be a 
different distribution of NK cell subsets between PB and BM (Figure 18B). In particular, 
it seems that at diagnosis CD56+cells present in the BM expressed low proportion of KIR 
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receptors. The analyses of CD107a expression upon incubation with K562 cell line 
revealed that during Nilotinib therapy a sharp increase of CD56+CD107a+ percentages both 
in PB and BM could be observed (Figure 18C). Finally, Figure 18D shows that BM-
derived NK cells expressed lower amounts of IFN-γ upon stimulation with IL-12, IL-15 
and IL-18 as compared to PB-derived NK cells. Notably, the percentages of BM-derived 
CD56+IFNγ+ cells increased during therapy either in the BM either in the PB. Finally, we 
observed that CD56+IL-22+ cells were more represented in BM as compared to PB. 
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Post 1 m 
BCR-
ABL1  
Post 3 m 
BCR-
ABL1  
Post 6 m 
BCR-
ABL1  
Post 9 m 
STKI001 CML-CP 31 M NIL ND 0,128% 0,028% 0,015% 
STKI003 CML-CP 43 F DAS 71,5 % 1,059 % 0,795 %      0,657 % 
STKI004 CML-CP 27 M NIL 9,9% 0,243% 0,035% 0,032% 
STKI005 CML-CP 36 M NIL 21% 0,42% 0,058% 0,059% 
STKI006 CML-CP 50 M IM-NIL 71% (1 M Nil 
46%) 
1,39% 1,38% 0,886% 
The patients’ samples were collected by the hematology clinic at the San Martino Polyclinic Hospital. 
CML-CP= Chronic Myeloid Leukemia- Chronic Phase 
m= month(s) 
M= Male, F= Female, IM= Imatinib, NIL= Nilotinib, DAS= Dasatinib 
% Of p210 copies 
<0,1% BCR-ABL1--> MMR; <0,01% BCR-ABL1--> DMR 
 
Table 1: This Table shows the reverse transcription quantitative polymerase chain reaction 
(RTqPCR) of BCR-ABL1 mRNA levels of patients affected by CML at different time 
intervals after therapy. The percentages refer to the contents of p210 copies in patients’ 
PB. This is a technique to evaluate if the patients responded to treatments and in some 




















Figure 13: Fresh PBMC have been isolated from peripheral blood of CML patients at 
diagnosis and at different time points after the start of therapy (1 month, 3 months, 6 
months and 12 months) and analyzed by flow-cytometry for the indicated surface markers. 
13A) Dot plots show the gating strategy used to identify CD56+ TOT, CD56dim and 
CD56bright. CD56+ cells were identified by the absence of lineage (CD3, CD14, CD19). 
13B) The histograms show the percentages of CD3+ and CD56+ cells in Nilotinib-treated 
patients and in the only one patient treated with Dasatinib. The data related to Nilotinib-
treated patients are represented as the median with interquartile range. 13C) The 













































































CD56+CD117+ cells in Nilotinib-treated patients and Dasatinib-treated patient. The data 
related to Nilotinib-treated patients are represented as the median with interquartile range. 
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Figure 14: Fresh PBMC have been isolated from peripheral blood of CML patients at 
diagnosis and at different time points after the start of therapy (1 month, 3 months, 6 
months and 12 months) and analyzed by flow-cytometry for the indicated surface markers, 
transcription factors (TF), CD107a expression and cytokines production. 14A) The 
histograms show the percentages of CD56+NKG2D+, CD56+DNAM-1+, CD56+NKp30+ 
and CD56+NKp46+. The data related to Nilotinib-treated patients are represented as the 
median with interquartile range. 14B) The histograms show the percentages of 




























































































































































































CD56+CD158e1/e1+ (KIR3DL1, DS1), CD56+CD158a,h+ (KIR2DL1, DS1), 
CD56+CD158b+ (KIR2DL2,DL3,DS2), CD56+CD94/NKG2a+ and CD56+CD94/NKG2c+ 
cells of Nilotinib-treated patients and Dasatinib-treated patient. The data related to 
Nilotinib-treated patients are represented as the median with interquartile range. 14C) The 
histograms show the percentages of CD56+CD107a+ of Nilotinib-treated patients and 
Dasatinib-treated patient compared to healthy donors. The data related to Nilotinib-treated 
patients are represented as the median with interquartile range. 14D) The histograms show 
the percentages of CD56+IFN-γ+ and CD56+IL-22+ of Nilotinib-treated patients and 
Dasatinib-treated patient compared to healthy donors. The data related to Nilotinib-treated 
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Figure 15: Expression of NKp46, NKp30, NKG2D and DNAM-1 CD56+NK cells 
activating receptors in Dasatinib- and Nilotinib-treated patients' PB at diagnosis and at 
different time intervals during therapy. MFI was analyzed by flow cytometry (Mean 
Positive - Mean Negative/2 Negative SD). The data are represented as the median with 









Figure 16: Fresh PBMC have been isolated from peripheral blood of CML patients at 
diagnosis and at different time points after the start of therapy (1 month, 3 months, 6 
months and 12 months) and analyzed by flow-cytometry for the indicated surface markers, 
RORγt TF and IL-22 cytokine production. 16A) Dot plots show the gating strategy for 
ILC3 detection. ILC3s were identified by the absence of lineage (CD3, CD14, CD19) and 
the expression of CD127, CD117 and RORγt markers. 16B) The histograms show the 
percentages of LIN-CD127+-ILC cells of Nilotinib-treated patients and Dasatinib-treated 
patient. The data related to Nilotinib-treated patients are represented as the median with 













































































interquartile range. 16C) The histograms show the percentages of RORγt+ cells IL-22+ 
cells gated on CD45+LIN-CD127+CD117+EOMES- cells detected in Nilotinib-treated 
patients and Dasatinib-treated patient compared to healthy donors. The data related to 






Figure 17: Fresh mononuclear cells have been isolated from peripheral blood and bone 
marrow of CML patients at diagnosis and after three months from the beginning of 
Nilotinib therapy and analyzed by flow-cytometry for the indicated surface markers. 17A) 
The histograms show the percentages of CD3+ and CD56+ cells in PB and BM of CML 
patients. The data are represented as the median with interquartile range. 17B) The 
histograms show the percentages of CD56dimCD16+, CD56brightCD16-, CD56+CD57+ and 











































































































Figure 18: Fresh mononuclear cells have been isolated from peripheral blood and bone 
marrow of CML patients at diagnosis and after three months from the beginning of 
Nilotinib therapy and analyzed by flow-cytometry for the indicated surface markers, 
CD107a expression and cytokines production. 18A) The histograms show the percentages 
of CD56+NKG2D+, CD56+DNAM-1+, CD56+NKp30+ and CD56+NKp46+ in PB and BM 



































































































































































































The histograms show the percentages of CD56+CD158e1/e1+ (KIR3DL1, DS1), 
CD56+CD158a,h+ (KIR2DL1, DS1), CD56+CD158b+ (KIR2DL2,DL3,DS2), 
CD56+CD94/NKG2a+ and CD56+CD94/NKG2c+ cells in PB and BM of CML patients  
18C) The histograms show the percentages of CD56+CD107a+ in PB and BM of CML 
patients. The data are represented as the median with interquartile range. 18 D) The 
histograms show the percentages of CD56+IFN-γ+ and CD56+IL-22+ in PB and BM of 








Figure 19: Expression of NKp46, NKp30, NKG2D and DNAM-1 CD56+NK cells 
activating receptors in Nilotinib-treated patients' PB and BM at diagnosis and after three 
months from the beginning of Nilotinib therapy. MFI was analyzed by flow cytometry 
(Mean Positive - Mean Negative/2 Negative SD). The data are represented as the median 













































































The second aim of my project was dedicated to the characterization of immune cell 
repertoire in CML patients undergoing TKI therapy. In view of our data obtained with the 
in vitro model of NK cell /ILC differentiation, we present and discuss our preliminary data 
regarding NK cells and ILC3, obtained in the five patients analyzed at diagnosis and 
during the first year of therapy. 
Overall, TKI therapy rapidly restored high percentages of circulating T lymphocytes while 
the percentages of NK cells did not significantly change.  Analyses of NK cell major 
subsets indicated that CD56bright decreased after beginning of TKI therapy and an increase 
of CD56dimCD16+CD57+ cells could be observed, particularly in Nilotinib-treated patients. 
It is important to remind that high percentages of CD56dimCD16+CD57+ cells have been 
correlated with a better molecular response in Imatinib and in Dasatinib-treated patients, 
while high percentages of CD56bright would correlate with a rapid molecular relapse 87, 88. 
The expression of activating receptors on CD56+ NK cells in Nilotinib- and Dasatinib-
treated patients displayed high variability during therapy. Dasatinib-treated patient 
presented very low percentages of NKG2D at diagnosis, however its expression increased 
during therapy treatment. In the same patient a major decrease of NKp30+ NK cells was 
observed at last time intervals paralleling the surface expression stabilization of NKG2D 
and DNAM-1 receptors. The expression of CD94/NKG2a on CD56+NK cells in Dasatinib 
treated patient was higher than in Nilotinib-treated patients. Of note, CD56+CD94/NKG2a+ 
cell percentages in Dasatinib-treated patient decreased after 12 months and remained at 
low percentages also in further analyses performed at 18 months of therapy (data not 
shown): at the same time intervals, the percentages of CD56+KIR2DL2/DL3/DS2+ cell 
subset increased in the same Dasatinib-treated patient.  Recently, in large cohort of CML 
patients, it has been shown that Dasatinib treatment induced a decrease of CD56+NKG2a+ 
NK cells that paralleled a higher NK cell cytotoxicity as compared to patients undergoing 
Imatinib and Nilotinib treatment 104. The evaluation of degranulation capability of NK cells 
subset revealed that both TKI drugs increased the percentages of NK cells expressing 
CD107a+ cells upon incubation with K562 leukemia cell line as compared to diagnosis. 
However, Nilotinib-derived CD56+cells displayed a reduction of degranulation capability 
after one year of therapy that may parallel the reduction of cytolytic activity that we 
observed in NK cells undergoing in vitro differentiation in the presence of this 
compound105.  On the other hand, Dasatinib-treated patient still displayed CD56+cells with 
a good degranulation capability at 12 months. These data would confirm that Dasatinib 
treatment might maintain stable NK cells cytotoxic activity against CML, also thank to a 
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good expression of activating receptors (i.e.NKG2D) and decreased expression of 
CD94/NKG2a inhibitory receptor on NK cells at the same interval. According to literature, 
the TKI-treated patients with high numbers of mature cytotoxic NK cells could be eligible 
to interrupt TKI therapy and achieved TFR 87, 91, 106, 107.  We observed that CD56+ NK cells 
developed in the presence of Dasatinib did not express CD94/NKG2a but displayed a 
reduced cytolytic activity in our in vitro NK/ILC differentiation studies 105. The different 
Dasatinib-mediated effect on NK cells cytotoxic activity detectable in vitro and in vivo 
may be related to short half-life of the drug in plasma patients vs. its durable and prolonged 
drug stimulation and/or cell activation status in in vitro experiments.  
Analyses of IFN-γ production by NK cells isolated from patient's PB suggested that TKI-
treated patients displayed increased proportions of IFN-γ+ cells upon therapy initiation, and 
IFN-γ expression remains stable during therapy both in Nilotinib- and Dasatinib-treated 
patients and was comparable to healthy controls. These data are in agreement with those 
obtained in our in vitro experiments showing that IFN-γ production was not affected but 
rather improved by TKI treatment105. Accordingly, our results also suggest that Dasatinib 
favored the production of IL-22 by CD56+ cells after the beginning of therapy. Our 
analyses for the identification of ILC helper subsets in PB revealed that Nilotinib patients 
displayed very low amounts of LIN-CD127+ cells. Of note, only Dasatinib-treated patient 
displayed clearly detectable percentages of LIN-CD127+.  These cells also expressed 
higher percentages of LIN-CD117+RORγt+ cells as compared to Nilotinib-treated patients 
until 6 months since the start of therapy. These data paralleled the higher percentages of 
LIN-CD127+CD117+IL-22+ cells detected in Dasatinib-treated patient as compared to 
Nilotinib-treated patients at the same times intervals. These preliminary results might 
represent a positive feedback of our data on Dasatinib-mediated effects on in vitro NK/ILC 
differentiation, suggesting a positive role of Dasatinib on ILC3 enrichment105.  
Recently, IL-22/IL-17 producing ILC3 have been detected in high percentages in 
malignant pleura effusion compared to the other ILC subtypes 108. Of note, it has been 
observed that pleural effusions are the more frequent side effect in Dasatinib-treated 
patients as compared to other TKI drugs 77. It has been reported that patients experiencing 
lymphocytosis during Dasatinib treatment had higher rates of PE that were also associated 
with improved response 92. We could analyze only one Dasatinib-treated patient 
(STKI003), who displayed low level of ILC3 and did not experienced PE, thus we can’t 
speculate any role for these cells. However, it would be useful to monitor Dasatinib 
patients who also develop side effects such as PE, colitis, autoimmune-like syndromes to 
observe whether there are any differences in ILC and NK cell repertoire as compared to 
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other TKI-treated patients or whether it could be any correlation with their clinical 
outcome.  
It has been demonstrated that BM microenvironment in hematological malignancies played 
a crucial role in hematopoietic stem cell differentiation, in the acquisition of the resistance 
to therapy and in disease relapse 94. TKI therapy has provided an important contribution in 
terms of molecular remission and prolonged survival of patients 66, 82. However, TKI drugs 
did not eliminate LSC (MRD) because these cells are quiescent and resistant to TKI-
induced apoptosis 109. Moreover, TKI therapy could interfere with normal hematopoiesis 
and then affected the generation of ILC and NK cells. In order to understand this, we 
analyzed ILC and NK cells repertoire in BM of Nilotinib-treated patients at diagnosis and 
three months after the therapy beginning. The results show that BM-derived NK cells in 
Nilotinib-treated patients were enriched in CD56brightCD16- expressing lower levels of 
activating receptors, any degranulation capability and lower capability to produce IFN-γ to 
NK cells isolated at diagnosis in the PB of the same patients.  In the last years, it has been 
suggested that NK cells isolated from ovarian carcinoma patients may express checkpoint 
inhibitors such as PD-1. We evaluated the expression of PD-1 both in the PB and in the 
BM of our patients, at diagnosis and during therapy. However, we could never observe 
detectable proportions of PD-1+NK cells (data not shown). Importantly, after three months 
of therapy, Nilotinib patients were in molecular remission and NK cells isolated from BM 
showed levels of CD16+ cells, of degranulation capability and of IFN-γ expression 
comparable to those observed in NK cells isolated from patients PB. 
Our preliminary data support the hypothesis that TKI may contribute to restore a functional 
NK cell repertoire and that Dasatinib may somehow modulate also ILC response and 
repertoire. It would be very important to perform parallel analyses on patients' BM and PB 
to obtain crucial information on the capability of immune system to control residual 
leukemic disease and to understand whether long lasting TKI-treated patients may achieve 
TFR.  In the next future we hope to continue our follow up with other patients and to 
complete our analyses on other cell populations such as T cells, myeloid-derived 
suppressor cells (MDSC), regulatory T cells (T reg) and on plasma samples that we 









4.5. MATERIAL AND METHODS  
 
CML Patients- Five patients affected by CML were identified as STKI001, STKI003, 
STKI004, STKI005 and STKI006 and included in our study until now. We received PB 
samples at diagnosis and at different time intervals. STKI001, STKI004 and STKI005 
received 300 mg of Nilotinib twice a day while STKI006 received 400 mg of Nilotinib 
twice daily. The analyses of PB were performed at different time intervals and we decided 
to show the data at diagnosis and after 1 month, 3 months, 6 months and 12 months (some 
patients were analyzed up for two years of Follow-up). All patients are still under TKI 
therapy. For  Nilotinib-treated patients, we were able to obtain medullary blood at 
diagnosis and three months after starting treatment (STKI001, STKI004, STKI005, 
STKI006). STKI001, STKI004 and STKI005 patients were in chronic phase at diagnosis 
and received Nilotinib as first-line treatment. STKI006 patient was in the chronic phase 
when started Nilotinib treatment upon failure of a first-line treatment with Imatinib. In the 
present work we report data analyzed at relapse after Imatinib failure, (i.e. before starting 
Nilotinib) and during Nilotinib treatment. STKI003 was in the chronic phase at diagnosis 
and is the only patient that underwent first-line treatment with Dasatinib. All these patients 
achieved a complete molecular remission. The serological detection of HCMV is negative 
in STKI003 patient, while the STKI001 and STKI006 patients have been positive 
(STKI004 and STKI005 patients' serology was not received). Nilotinib-treated patients and 
Dasatinib-treated patient had no side effects and have not been affected by viral infections 
or re-activation (CMV/EBV) neither experienced any severe bacterial infections. The 
QRT-PCR for BCR-ABL1 mRNA transcript has been performed after the beginning of 
TKI therapy.	
Cell isolation and plasma collection- Hematology clinic at the San Martino Polyclinic 
Hospital samples provided CML patients’ samples. Ethical Committee approved the study 
and patients gave their written informed consent according to the Helsinki Declaration. 
Mononuclear cells were obtained by Ficoll-Lympholyte (Cedarlane, Canada) separation. 
Plasma were collected and stored at -80°. 
7-color immunophenotyping- Cocktail of fluorochrome-conjugated monoclonal 
antibodies, human contains: αCD14 (clone: Tük4) FITC, αCD56 (clone: REA196) PE, 
αCD16 (clone: VEP13) PE αCD4 (clone: VIT4) PerCP, αCD19 (clone: LT19) PE-Vio770, 
αCD3 (clone: BW264/56) APC, αCD8 (clone: BW135/80) APC-Vio770, αCD45 (clone: 
5B1) VioBlue (Miltenyi Biotec). Immunofluorescent staining of whole blood (lyse/no 
wash): 50 µL of whole blood incubate with cocktail for ten minutes in the dark at 4°C. 
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After, were added lysis solution and incubate for 15 minutes in the dark at room 
temperature. Finally, cells suspension was analyzed immediately to the flow cytometer. 
Monoclonal antibodies (mAbs) and Flow Cytometry- mAbs were purchased from 
several companies. A full list of the mAbs utilized is provided in Table 1. All the mAbs 
were mouse-anti human. Cell viability were determined using Viobility 405/520 Fixable 
Dyes (Miltenyi Biotec) to exclude dead cells.  
Intra-cytoplasmic cytokine and TF expression assays- To detect cytokines, cells are 
overnight stimulated with IL-12 (10 ng/ml), IL-15 (50 ng/ml), IL-18 (100 ng/ml) or IL-1β 
(50 ng/ml), IL-7 (50 ng/ml), IL-23 (50 ng/ml) (PeproTech, UK) in the presence of 
monensin (GolgiStop) or brefeldin (GolgiPlug) (BD Biosciences), respectively. For intra-
cytoplasmic cytokine analyses, cells were stained for surface markers and then fixed and 
permeabilized with Fixation and Permeabilization Kit (BD Biosciences, New Jersey USA). 
Then, cells were incubated with cytokine-specific mAbs. To detect TF expression, cells 
were suspended in 5% BSA buffer, stained for surface markers, subsequently fixed with 
Transcription Factor Staining Buffer Set (eBioscience-ThermoFisher) and stained for 
RORγt. 
CD107a degranulation assay- Patient’s lymphocytes were in vitro stimulated for 72h 
with IL-15 (25ng/ml) and then incubated for were incubated in 1/1 ratio with the human 
erythroleukemia cell line K562 in the presence of the αCD107 for 3-hours. Monensin 
(GolgiStop, BD) was added after one hour of incubation to the cells. At the end of the 
incubation the cells were collected and marked to surface immunofluorescence and 
analyzed on the flow cytometer. 
Real Time-Reverse Transcription-Polymerase Chain Reaction (RT-PCR) – Total 
RNA was extracted from mononucleated cells derived from PB and BM of CML patients 
at different time points (1 month, 3 months, 6 months and 9 months). RNA was 
synthesized into cDNA according to standard procedures in the SuperScript IV One-Step 
RT-PCR pre-amplification system kit (Invitrogen, Rockville, MD). The BCR-ABL1 
transcripts were amplified using the following primers: 5’- GAG CAG CAG AAG AAG 
TGT TTC AGA-3’ (BCR-P210-F exons 12/13), 5’- CAA CAG TCC TTC GAC AGC AG-
3’ (BCR-P190-F exon 1), 5’- CTT GGA GTG AGG CAT CTC AG-3’ (ABL1-R exon 10), 
5’- CAT CAT TCA ACG TGT GCC GAC GG-3’ (ABL1 A fragment exon 4), 5’- GTT 
GCA CTC CCT CAG GTA GTC-3’ (ABL1 A fragment exon 6), 5’- GAA GAA ATA 
CAG CCT GAC GGT G-3’ (ABL1 B fragment exon 4), 5’- CGT CGG ACT TGA TGG 
AGA A-3’ (ABL1 B fragment exon 7), 5’- TGG TAG GGG AGA ACC ACT TG-3’ 
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(ABL1 C fragment exon 7), 5’- CCT GCA GCA AGG TAC TCA CA-3’ (ABL1 C 





Table 2- List of mAbs used in the experiments. 
 
Antigen Antibody clone Fluorochrome Supplier 
CD56 N901 PeCy7 Beckman-Coulter 
CD159a Z199 APC Beckman-Coulter 
CD159a Z199 PE Beckman-Coulter 
CD158a EB6B APC Beckman-Coulter 
CD158a EB6B PE Beckman-Coulter 
CD158b1,b2 GL183 APC Beckman-Coulter 
CD158b1,b2 GL183 PE Beckman-Coulter 
CD158e1,e2 Z27.3.7 APC Beckman-Coulter 
CD158e1,e2 Z27.3.7 PE Beckman-Coulter 
CD3 SK7 APC-eFluor-780 
eBioscience-
ThermoFisher 
CD3 SK7 eFluor450 eBioscience-ThermoFisher 
CD3 BW264/56 FITC Miltenyi Biotec 
CD33 REA775 VioGreen Miltenyi Biotec 
CD33 AC104.3E3 APC Miltenyi Biotec 
CD14 TÜK4 FITC Miltenyi Biotec 
CD14 61D3 eFluor450 eBioscience-ThermoFisher 
CD14 61D3 APC-eFluor-780 
eBioscience-
ThermoFisher 
HLA-DR AC122 PerCP Miltenyi Biotec 
CD16 REA423 FITC Miltenyi Biotec 
CD16 3G8 BV-421 BioLegend 
CD16 3G8 PerCP BioLegend 
CD117 104D2 BV-421 eBioscience-ThermoFisher 
CD117 (c-KIT) 104D2 PerCP-Cy5.5 BioLegend 
NKG2C FAB138P AF-488 R&D systems 
CD226  
(DNAM-1) 11A8 PE BioLegend 
CD335 (NKp46) 9E2 eFluor450 BioLegend 
CD336 (NKp44) P44-8 AF-647 BioLegend 
CD337 (NKp30) P30-15 AF-647 BioLegend 
CD127 A019D5 BV-421 BioLegend 
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Antigen Antibody clone Fluorochrome Supplier 
CD127 A019D5 PerCP-Cy5.5 BioLegend 
CD34 4H11 PE eBioscience-ThermoFisher 
CD15 W6D3 FITC Miltenyi Biotec 
CD19 HIB19 APC-eFluor-780 
eBioscience-
ThermoFisher 
CD19 HIB19 eFluor450 eBioscience-ThermoFisher 
CD4 M-T466 VioGreen Miltenyi Biotec 
CD8 BW135/80 APC Miltenyi Biotec 
CD25 M-A251 BV-421 BD Biosciences 
CD39 TU66 FITC BD Biosciences 
CD45 2D1 FITC eBioscience-ThermoFisher 
CD57 HCD57 PB Biolegend 
CD69 FN50 FITC Miltenyi Biotec 
IL-22 22URTI PE eBioscience-ThermoFisher 
ROR-γt AFKJS-9 PE eBioscience-ThermoFisher 
EOMES WD1928 eFluor-660 eBioscience-ThermoFisher 
IFN-γ 4S.B3 PerCP-Cy5.5 eBioscience-ThermoFisher 
IFN-γ 4S.B3 eFluor450 eBioscience-ThermoFisher 
TNF-α MAb11 eFluor450 eBioscience-ThermoFisher 
FOXp3 259D/C7 AF-647 BD Biosciences 
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Tyrosin kinase inhibitors (TKI) sharply improved the prognosis of Chronic Myeloid
Leukemia (CML) and of Philadelphia+ Acute Lymphoblastic Leukemia (Ph+ALL) patients.
However, TKI are not curative because of the development of resistance and
lack of complete molecular remission in the majority of patients. Clinical evidences
would support the notion that patient’s immune system may play a key role in
preventing relapses. In particular, increased proportions of terminally differentiated
CD56+CD16+CD57+ NK cells have been reported to be associated with successful
Imatinib therapy discontinuation or with a deep molecular response in Dasatinib-treated
patients. In view of the potential role of NK cells in immune-response against
CML, it is important to study whether any TKI have an effect on the NK cell
development and identify possible molecular mechanism(s) by which continuous
exposure to in vitro TKI may influence NK cell development and repertoire. To
this end, CD34+ hematopoietic stem cells (HSC) were cultured in the absence or
in the presence of Imatinib, Nilotinib, or Dasatinib. We show that all compounds
exert an inhibitory effect on CD56+ cell recovery. In addition, Dasatinib sharply
skewed the repertoire of CD56+ cell population, leading to an impaired recovery
of CD56+CD117−CD16+CD94/NKG2A+EOMES+ mature cytotoxic NK cells, while
the recovery of CD56+CD117+CD94/NKG2A−RORγt+ IL-22-producing ILC3 was not
affected. This effect appears to involve the Dasatinib–mediated inhibition of Src kinases
and, indirectly, of STAT5-signaling activation in CD34+ cells during first days of culture.
Our studies, reveal a possible mechanism by which Dasatinib may interfere with the
proliferation and maturation of fully competent NK cells, i.e., by targeting signaling
pathways required for differentiation and survival of NK cells but not of ILC3.
Keywords: innate lymphocyte cells, NK cell development, tyrosin kinase inhibitors, CML-chronic myelogenous
leukemia, ILC3
INTRODUCTION
Therapy with tyrosin kinase inhibitors (TKI) has greatly improved the prognosis of Chronic
Myeloid Leukemia (CML) and of Philadelphia+ Acute Lymphoblastic Leukemia (Ph+ALL)
patients (1–3). However, despite their efficacy, TKI cannot be considered as curative therapeutic
agents, because the majority of patients develop resistance or lack complete molecular remission
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(4–6). Moreover, patients undergoing life-long treatment may
experience adverse effects that compromise their quality of life
(6–8). Thus, during the past several years, the achievement of
therapy discontinuation, allowing long treatment-free remissions
(TFR) became a main area of investigation (8). Recent clinical
trials indicated that ∼40% of patients with deep molecular
response (DMR), who undergo therapy discontinuation, remain
free of relapse for several years (8–10). Clinical evidences would
support the notion that the patient’s immune system may play a
key role either by eradicating leukemia or by exerting a successful
long-lasting control of residual leukemic cells. Indeed, patients
with an efficient effector arm of their immune system display
a significantly longer TFR with a DMR (11–13). Thus, ongoing
major efforts are aimed to identify immune mechanisms and
biomarkers that may help to select patients who are suitable for
successful therapy discontinuation upon achievement of a DMR.
In this context, analysis of natural killer (NK) cells, capable of a
potent anti-leukemia activity, could offer a clue to identify such
patients (14).
NK cells represent an important component of the innate
immunity. Their function is finely tuned by inhibitory and
activating receptors. Remarkably, NK cells have been shown
to play an important role in the favorable clinical outcome
of patients with high risk leukemias undergoing haploidentical
Hematopoietic Stem Cell Transplant (15–18). NK cells can
recognize and kill leukemic blasts, particularly those displaying
down-regulation of HLA-class I molecules (failing to interact
with HLA-specific inhibitory NK receptors such as KIR and
CD94/NKG2A), and/or over-expressing ligands recognized by
activating NK receptors (including Natural Cytotoxic Receptors,
NCR, NKG2D and DNAM-1) (16, 19). Certain activating KIR,
present only in some individuals, may also positively contribute
to the anti-leukemia activity (14, 20, 21).
NK cell development occurs primarily in the bone marrow
(BM), requires the expression of E4BP4 (NFIL3), Tbx21
(T-bet), eomesodermin (EOMES) transcription factors (TF),
and proceeds through a multi-step process, characterized
by the sequential acquisition of surface receptor markers
(including CD161, CD56, CD94/NKG2A, LFA-1, CD16, KIRs,
and CD57) and given functional capabilities (22–24). NK
cells are developmentally related to Innate Lymphoid Cells
(ILCs) as they derive from a common DNA-binding protein
inhibitor (ID2)-positive hematopoietic precursor (24). Members
of ILC family are thought to play a relevant role in innate
defenses against pathogens, in epithelial tissue homeostasis
and in lymphoid structure organization. Three main groups
of ILCs have been identified: ILC1, ILC2, and ILC3, on
the basis of their cytokine profile and transcription factors
(TF) required for their differentiation (25). In vitro models
of human NK cell development from umbilical cord blood
(UCB)-derived CD34+ cells revealed that these precursors
can give rise both to NK cells and ILC3. The expression of
CD94/NKG2A and LFA-1 marks CD161+CD56+CD117−CD7+
NK cells that express NCR, cytolytic granules and production
of IFN-γ. On the other hand, the lack of expression of
CD94/NKG2A and LFA-1 (CD161+CD56+CD117+CD7−LFA-
1−CD94/NKG2A−) identifies a heterogeneous cell subset,
that may contain both NK cell precursors and ILC3,
characterized by the expression of RAR-related orphan
receptor gamma (RORγt) TF and by the ability to produce
IL-22 (26, 27).
In the past few years, the effects of TKI on the NK cell
repertoire and function have been analyzed in several studies
(28). Of note, increased proportions of terminally differentiated
cytolytic CD56+CD16+CD57+ NK cells were found in patients
that achieved a successful Imatinib therapy discontinuation or in
Dasatinib-treated patients with a DMR (12, 29–32). Recently, it
has also been suggested that KIR genotype may represent a new
biomarker for response to TKI therapy (33–35). On the other
hand, previous in vitro studies reported conflicting results on the
effect of different TKI on NK cell proliferation and function (28).
In view of the potential role of NK cells in the control of
CML, it is important to study the effect of TKI not only on
mature NK cells, but also on NK cells undergoing maturation.
Notably, TKI may impair hematopoiesis, consequent to the
inhibitory effect on c-KIT transduction pathway. Moreover,
Dasatinib inhibits Src kinase, also involved in the regulation of
hematopoiesis. Thus, it is possible that prolonged administration
of TKI may affect NK cell differentiation from Hematopoietic
Stem Cells (HSC) (24, 36–38). To explore this possibility,
whether indeed TKI could influence NK cell development
and repertoire, UCB-derived CD34+ HSC were cultured in
the absence or in the presence of Imatinib, Nilotinib, or
Dasatinib. Our results show that all compounds exert an
inhibitory effect on cell proliferation. In addition, Dasatinib
sharply skewed the repertoire of CD56+ cells, with an impaired
recovery of CD56+CD117−CD16+CD94/NKG2A+EOMES+
mature cytotoxic NK cells, paralleled by an enrichment
of CD56+CD117+CD94/NKG2A−RORγt+ ILC3. This effect
appears to involve the Dasatinib–mediated inhibition of Src
kinases. Our studies, revealed a mechanism by which Dasatinib
may interfere with the maturation of fully competent NK cells,
i.e., by targeting signaling pathways required for differentiation
of NK cells but not of ILC3.
MATERIALS AND METHODS
Cell Isolation and in vitro Culture
Liguria Cord Blood Bank provided UCB samples from healthy
individuals. Ethical Committee approved the study and
mothers gave their written informed consent according to
the Helsinki Declaration. Mononuclear cells were obtained
by Ficoll-Lympholyte (Cedarlane, Canada) separation.
CD56−CD34+ cells (>98% purity) were obtained by MACS
positive separation (Miltenyi Biotec, Germany). Cells were
cultured in RPMI 1640 (Lonza, Belgium) containing 10%
human AB serum (Biowest, France), Stem Cell Factor (SCF)
(10 ng/ml), Fms-related tyrosine kinase 3 ligand (FLT3-L)
(10 ng/ml), Interleukin-7 (IL-7) (20 ng/ml), Interleukin-15
(IL-15) (20 ng/ml), Interleukin-21 (IL-21) (20 ng/ml) (Miltenyi
Biotec,), in the absence or in the presence of: Imatinib (IM
5µM), Nilotinib (NIL 3, 6µM), Dasatinib (DAS 200 nM)
(Selleck Chemicals, USA) at the plasma concentration 30min
post administration, or with Dimethyl sulfoxide (DMSO) at the
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corresponding concentration of the drugs (D 1:1,000/1:25,000)
(Sigma-Aldrich, USA) or with KX2-391 used at different
concentrations (Selleck Chemicals). We added TKI, DMSO,
or KX2-391 at day 0 and at later intervals i.e., 24 h, 4, 10, or
15 days.
Monoclonal Antibodies (mAbs) and Flow
Cytometry
mAbs were purchased from several companies. A full list of the
mAbs utilized is provided in Table 1. All the mAbs were mouse-
anti human, with the exception of ROR-γt mAb, Phospho-Stat3
(Tyr705)(D3A7)XP mAb, and Phospho-Stat5 (Tyr694)(D47E7)
XP mAb were from Rabbit. To perform cell gating strategy we
first identifiedmorphological parameters using FSC-A vs. SSC-A.
Then, we performed a further gate in which we analyze the FSC-A
vs. FSC-H, in order to limit any interference due to doublets. To
assess cell viability we performed analyses with Propidium Iodide
and Annexin V.
Cell Cytotoxicity Assay
Cell cytotoxicity was analyzed in a 4 h 51Cr-release assay against
human leukemic K562 cell line. Cells were counted, washed
and plated. Effector/Target (E/T) cell ratio is 2/1. The effector
target ratio was normalized to the numbers of CD56+ cells
present in each culturing conditions. To this end, we adjusted
the number of effector cells in each condition accordingly to
the CD56+ cells present in the cultures and to the cell count
performed simultaneously by using MACSQuant flowcytometer.
Experiments were performed in duplicates. Data are expressed as
percentage of target cell lysis.
Intra-cytoplasmic Cytokine, Cytolytic
Granules, and TF Expression Assays
To detect cytokines, cells cultured in different conditions,
were washed, suspended and over night stimulated with IL-
12 (10 ng/ml), IL-15 (50 ng/ml), IL-18 (100 ng/ml), or IL-
1β (50 ng/ml), IL-7 (50 ng/ml), IL-23 (50 ng/ml) (Peprotech,
UK) in the presence of monensin (GolgiStop) or brefeldin
(GolgiPlug) (Biosciences), respectively. For intra-cytoplasmic
cytokine and cytolytic granules analyses, cells were stained
for surface markers and then fixed and permeabilized with
Fixation and Permeabilization Kit (BD Biosciences, New Jersey
USA). Then, cells were incubated with cytokine- or Perforin-
specific mAb. To detect TF expression, cells were suspended
in 5% BSA buffer, stained for surface markers, subsequently
fixed with Transcription Factor Staining Buffer Set (eBioscience-
ThermoFisher) and stained for RORγt, and EOMES TF; instead,
to detect expression of pSTAT3 and pSTAT5, cells were fixed with
PFA 4% andmethanol 100% and after that cells were stained with
anti-pSTAT antibodies.
Statistical Analysis
Prism GraphPad software was used for statistical analysis. We
considered significant P ≤ 0.05.




CD56 N901 PeCy7 Beckman-Coulter
CD159a Z199 APC Beckman-Coulter
CD159a Z199 PE Beckman-Coulter
CD158a EB6B APC Beckman-Coulter
CD158b1,b2 GL183 APC Beckman-Coulter
CD158e1,e2 Z27.3.7 APC Beckman-Coulter
CD158a EB6B PE Beckman-Coulter
CD158b1,b2 GL183 PE Beckman-Coulter
CD158e1,e2 Z27.3.7 PE Beckman-Coulter
CD336 (NKp44) Z231 PE Beckman-Coulter
CD337 (NKp30) Z25 PE Beckman-Coulter
CD335 (NKp46) BAB281 PE Beckman-Coulter
CD33 AC104.3E3 APC Miltenyi Biotec
CD14 TÜK4 FITC Miltenyi Biotec
HLA-DR AC122 PerCP Miltenyi Biotec
CD16 REA423 FITC Miltenyi Biotec
CD11a (LFA-1) TS2/4 PerCP BioLegend
CD11a (LFA-1) TS2/4 FITC BioLegend
CD7 CD7-6B7 FITC BioLegend
CD335 (NKp46) 9E2 eFluor450 BioLegend
CD117 (c-KIT) 104D2 PerCP-Cy5.5 BioLegend
CD161 HP-3G10 PerCP-Cy5.5 BioLegend
CD226 (DNAM-1) 11A8 PE BioLegend
CD94 DX22 FITC BioLegend
CD336 (NKp44) P44-8 AF-647 BioLegend
CD337 (NKp30) P30-15 AF-647 BioLegend
CD16 3G8 BV-421 BioLegend
CD127 A019D5 BV-421 BioLegend
CD132 TUGh4 APC Biolegend
CD14 61D3 eFluor450 eBioscience-
ThermoFisher
CD117 104D2 BV-421 eBioscience-
ThermoFisher
CD14 61D3 APC-eFluor-780 eBioscience-
ThermoFisher
IL-22 22URTI PE eBioscience-
ThermoFisher
ROR-γt AFKJS-9 PE eBioscience-
ThermoFisher
EOMES WD1928 eFluor-660 eBioscience-
ThermoFisher
Perforin dG9 PE eBioscience-
ThermoFisher
IFN-γ 4S.B3 eFluor450 eBioscience-
ThermoFisher
TNF-α MAb11 eFluor450 eBioscience-
ThermoFisher
CXCL8 6217 PE R & D system
pSTAT3 XP rabbit
(Tyr705)
D3A7 Unconjugated Cell signaling
pSTAT5 XP rabbit
(Tyr694)
D47E7 Unconjugated Cell signaling
Goat-anti rabbit
(IgG H + L) IgG1
A27034 AF-488 Invitrogen-
ThermoFisher
CD122 Mik-β2 PE BD Pharmingen
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RESULTS
TKI Inhibit in vitro Proliferation of Myeloid
and Lymphoid Precursors From CD34+
HSC
In order to analyze the effects of different TKI on in vitro
NK cell differentiation, UCB-CD34+ HSC were isolated and
cultured with cytokines (SCF, FLT3-l, IL-7, IL-15 and IL-21,
see section Material and Methods), suitable to promote NK
cell differentiation, either in the absence (control = CTR) or
in the presence of different TKI at plasmatic concentrations:
Imatinib 5µM (IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM
(DAS). DMSO was used as vehicle control. After 15 days of
culture, cells were counted and analyzed for informative surface
markers. As shown in Figure 1A, TKI led to a decreased
mono-nucleated cell recovery that was particularly sharp in
the case of Dasatinib. Evaluation of the surface staining for
Annexin V after 3 and 8 days of culture suggested that the
strong reduction of cell numbers detected in the presence of
Dasatinib may be due to an increased programmed cell death,
occurring during the first week of culture (Figure 1B). The
analysis of informative cell surface markers indicated that the
recovery of both CD33+CD14− myeloid cells and CD33+CD14+
monocytes, was sharply reduced in the presence of all TKI
analyzed (Figure 1C). Remarkably, all TKI induced a significant
reduction of CD161+CD56+ absolute cell numbers as compared
to controls. Also in this case, the effect was most striking in
the presence of Dasatinib (Figure 1D). Of note, results obtained
in cultures performed in the presence of Dasatinib displayed a
sharp significant difference also with cultures performed in the
presence of DMSO 1:25,000 (Figures 1A,C,D). Since cultures
performed with DMSO at the final concentrations of 1:25,000 did
not substantially differ in cell recovery from the CTR cultures,
data on the cultures performed with DMSO at this concentration
will not be shown any further.
Dasatinib Skews in vitro Cell Differentiation
of CD161+CD56+ Precursors Toward ILC3
Next, we analyzed the surface phenotype of CD161+CD56+
cells obtained after 25 days under the culture conditions
indicated above. As shown in Figure 2A, analysis of the receptor
repertoire of CD56+ cells revealed a significant reduction
of CD56+CD94/NKG2A+ cells in the presence of Dasatinib,
while the percentages of CD56+CD117+ cells were significantly
increased. Accordingly, also the percentages of NKG2D+,
DNAM-1+, and CD16+ cells were reduced as compared
to controls (Figure 2B). Figure 2C shows a representative
experiment: in the presence of Dasatinib, a major decrease of
percentages of CD56+ cells could be detected. Moreover, the
majority of CD56+ cells were represented by CD117+LFA-
1−CD94/NKG2A−CD16− cells, a subset that may include
both ILC3 and Stage III NK cell precursors (27). Thus, we
further analyzed the expression of RORγt and Eomes TF,
which allows discriminating ILC3 and stage IV/V NK cells.
This analysis revealed a significant increase of CD56+ RORγt+
ILC3 and a significant decrease of CD56+ Eomes+ NK cells as
compared to controls (Figures 3A,B), Of note, we could detect
higher percentages of CD56+CD117+CD127+(CD132+) cells in
cultures performed in the presence of Dasatinib as compared
to controls, while CD122+ cells were virtually undetectable
(Figure 3C).
CD161+CD56+ Cells Developed in the
Presence of Dasatinib Express Higher
Percentages of IFN-γ+ Cells but Display a
Reduced Cytolytic Activity
The altered composition of CD56+ cell subsets occurring in
the presence of Dasatinib, suggests that this compound may
affect NK cell differentiation and proliferation. To verify whether
TKI could also affect the functional activity of CD56+ cells,
we analyzed the intra-cytoplasmic cytokine expression and
the cytolytic activity against the NK-susceptible K562 human
leukemia cell line.
CD56+ lymphoid cells, developed in the absence or in
the presence of different TKI, were stimulated either with
IL-1β, IL-7, and IL-23, or with IL-12, IL-15, and IL-18 and
analyzed for intra-cytoplasmic cytokine expression by flow
cytometry. Figures 4A,B shows that CD56+CD117+CD94−
ILC3 subset, generated in the presence of Dasatinib, display
higher percentages of IL-22+ and IL-8+ cells and a slight increase
of IFN-γ+ cells. Interestingly, in the presence of Dasatinib, also
the small CD56+CD117−/+CD94+ cell subset, expressed higher
proportions of IFN-γ+ cells as compared to the other culturing
conditions (Figures 4A,B). Analysis of the cytolytic activity
against K562 target cells, indicated that CD56+ cells generated
in the presence of Nilotinib or Dasatinib, were significantly
less cytolytic (Figure 4C). Of note, the decreased cytotoxicity,
observed in the presence of Dasatinib, was associated to lower
percentages of CD56+ Perforin+ cells as compared to controls
(Figure 4D).
Inhibition of Src Kinases Skews CD56+
Cell Repertoire Undergoing in vitro Cell
Differentiation
It has been reported that Dasatinib, but not Imatinib and
Nilotinib, exerts an inhibitory effect on the family of Src kinases:
thus, it is possible that the lower numbers of CD56+ cells,
detected in the presence of this compound, may reflect an
inhibitory effect on Src kinases occurring at the level of cell
precursors (36, 39). To test this possibility, CD34+HSC were
cultured in appropriate cytokine mix medium in the absence
or in the presence of different concentrations of KX2-391 (5,
50, 100, and 200 nM) a non-selective Src kinase inhibitor, or in
the presence of Dasatinib (200 nM). After 15 days of culture,
cells were counted. KX2-391 did not significantly impair cell
proliferation at different drug concentrations with the exception
of highest dose (200 nM), in which an extensive cell death could
be detected (Figures 5A,B). Moreover, there were no significant
variations in CD56+ cell percentages in the presence of lower
concentrations of KX2-391 inhibitor as compared to controls
(Figure 5C). However, analysis of the cell surface phenotype
revealed that KX2-391 could induce substantial modifications of
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FIGURE 1 | TKI inhibit the in vitro cell differentiation of CD34+HSC toward myeloid and lymphoid cells. UCB-CD34+ cells were purified and cultured with
cytokine-mix medium in the absence (CTR, control) or in the presence of different TKI: Imatinib 5µM (IM) Nilotinib 3,6µM (NIL), Dasatinib 0,2µM (DAS) at the plasma
peak concentrations and DMSO at the corresponding concentrations of the drugs (D 1:1000 and D 1:25000). After 15 days of culture, cells were counted and
analyzed by flow-cytometry for the indicated surface markers. (A) The histogram shows the absolute mononucleated cell number recovery in CTR or TKI cultures. The
data are represented as the median with interquartile range obtained by ten independent experiments and analyzed by Kruskal-Wallis multiple comparison test (*p <
0.05;**p < 0.005;***p < 0.0005). (B) Dot plots show the morphological features and Annexin V/PI staining observed in the cell precursors undergoing in vitro NK cell
differentiation in the presence of different culturing conditions: control (CTR), Imatinib 5µM (IM), Nilotinib 3,6µM (NIL), Dasatinib 0,2µM (DAS) and DMSO (D 1:1000
and D 1:25000). The cells were undergone to immunofluorescence tests after 3 and 8 days of culture. (C) The histogram represents the fold change of absolute cell
numbers of CD33+CD14− and CD33+CD14+ cells recovered in TKI and DMSO cultures as compared to CTR, arbitrarily normalized to one. The data are expressed
as the median values with interquartile range obtained by ten independent experiments. Data obtained in different culturing conditions were compared to CTR and
analyzed by Wilcoxon signed-rank test (*p < 0.05;**p < 0.005;***p < 0. 0005;****p < 0.00005). Comparison between the different TKI culturing conditions and the
different DMSO diluition culturing conditions was analyzed by Kruskal–Wallis multiple comparison test (*p < 0.05; **p < 0.005). (D) The histogram represents the fold
change of CD161+CD56+ absolute cell number recovered in the presence of TKI and DMSO as compared to CTR, arbitrarily normalized to one. Data are
represented as the median values with interquartile range obtained by ten independent experiments and comparison with CTR was analyzed by Wilcoxon signed-rank
test (*p < 0.05;**p < 0.005). Comparison between the different TKI culturing conditions and the different DMSO dilution culturing conditions was analyzed by
Kruskal–Wallis multiple comparison test (*p < 0.05).
Frontiers in Immunology | www.frontiersin.org 5 October 2018 | Volume 9 | Article 2433
Damele et al. Dasatinib Impairs NK Cell Development
FIGURE 2 | Dasatinib inhibits NK cell generation from CD34+ precursors. CD161+CD56+ cells developed in the absence (CTR) or in the presence of Imatinib 5µM
(IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM (DAS) and DMSO 1:1000 (D 1:1000) were analyzed after 25 days of culture for the expression of the indicated surface
markers. (A) The histogram represents the fold change of CD161+CD56+CD117+, CD161+CD56+CD94/NKG2A+, and CD161+CD56+LFA-1+ cell percentages,
detected in the presence of the indicated TKI or DMSO, as compared to CTR cultures, arbitrarily normalized to one. Data are expressed as mean values ± SEM
obtained by ten independent experiments and analyzed by Wilcoxon signed-rank test (*p < 0.05;**p < 0.005). (B) The histogram represents the fold change of
CD161+CD56+ cell percentages expressing NKp46, NKp30, NKp44, NKG2D, DNAM-1, KIR, and CD16 receptors, developed in the presence of the indicated TKI or
DMSO as compared to CTR cultures, arbitrarily normalized to one. Data are expressed as mean values ± SEM of ten independent experiments and analyzed by
Wilcoxon signed-rank test (*p < 0.05). (C) Flow cytometric analyses show surface staining for the indicated surface markers expressed by CD161+CD56+ cells
obtained after 25 days of culture in the absence (CTR) or Dasatinib 0.2µM (DAS). Representative experiment out of ten.
the subset composition within the CD56+ cell population, similar
to those detected in the presence of Dasatinib. Thus, as shown in
Figures 5D,E, even in the presence of the lowest concentration of
KX2-391 (i.e., 5 nM), there was an increased expression of RORγt
TF and of CD117, paralleled by the reduced expression of Eomes
TF and of CD94/NKG2A. Accordingly, CD56+ cells undergoing
differentiation in the presence of Dasatinib 200 nM or KX2-391
5 nM, displayed a lower cytolytic activity against K562 target cells
as compared to control (Figure 5F).
It has been shown that Dasatinib can inhibit the Signal
Transducer and Activator of Transcription (STAT) 3 and STAT
5 protein phosphorylation through the inhibition of Src kinases.
Thus, the Dasatinib–mediated effects could also be due to
the inhibition of STAT3/STAT5 signaling pathways. To address
this issue we investigated whether Dasatinib could inhibit
STAT3/STAT5 phosphorylation in CD34+ cell precursors since
early days of in vitro culture. Thus, CD34+ cells were cultured
with cytokine mix medium in the absence or in the presence of
Dasatinib, and STATs protein phosphorylation was analyzed at
different time intervals, i.e., 18/24/48 h of culture. A reduction
of pSTAT5+ cell percentages was detected while the percentages
of pSTAT3+ cells were similar or higher than those detected in
control cultures at all the time intervals analyzed (Figure 6A).
Of note, after 72 h of culture in the presence of Dasatinib, we
could still observe lower pSTAT5+ cell percentages as compared
to control, and increase of CD117+ cell percentages (Figure 6B).
On the other hand, analysis performed at 20 days of culture,
showed that CD56+ cell subsets developed in the presence of
Dasatinib, contained higher percentages of pSTAT5+ cells as
compared to controls, while myeloid cells displayed a marked
reduction of both pSTAT3+ and pSTAT5+ cells (Figure 6C).
DISCUSSION
In this study we analyzed the effect of the TKI inhibitors
Imatinib, Nilotinib, and Dasatinib on NK cell differentiation
from UCB-derived CD34+ cell precursors. We show a sharp
inhibition of cell proliferation and a reduced recovery of both
myeloid and CD161+CD56+ lymphoid cells. More importantly,
Dasatinib skewed the subset composition of CD161+CD56+
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FIGURE 3 | Dasatinib affects the CD56+ cell repertoire, favoring the enrichment of CD56+CD117+CD94/NKG2A−RORγt+ ILC3. CD161+CD56+ cells developed in
the absence (CTR) or in the presence of Imatinib 5µM (IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM (DAS) and DMSO 1:1000 (D 1:1000) were analyzed by
flow-cytometry after 25 days of culture for the expression of transcription factors (TF). (A) The histogram represents the fold change of CD56+RORγt+ and
CD56+EOMES+ cell percentages, obtained in the presence of the indicated TKI or DMSO, as compared to CTR, arbitrarily normalized to one. Data are expressed as
median values with interquartile range obtained by ten independent experiments and analyzed by Wilcoxon signed-rank test (**p < 0.005). (B) Dot plots show
intra-nuclear staining of RORγt and EOMES after gating on CD33−CD161+CD56+ cells, developed in the absence (CTR) or in the presence of the indicated TKI or
DMSO. Representative experiment out of ten performed. (C) UCB-CD34+ cells were purified and cultured with cytokine-mix medium in the absence (control=CTR) or
in the presence of Dasatinib 200 nM. After 6 days of culture cells were analyzed by flow-cytometry for the indicated surface markers. Flow cytometric analysis show
representative experiment out of two.
cell population favoring the generation of RORγt+IL-22+ ILC3
and inhibiting both proliferation and function of cytotoxic NK
cells. Experiments using the KX2-391 Src-family kinase inhibitor
suggest that the impairment of NK cell generation and function
may be consequent to the inhibitory effect mediated by Dasatinib
on Src-family kinases and the early impairment of STAT5
signaling in CD34+ cell precursors.
The TKI therapy in CML or Ph+ALL patients has dramatically
improved the prognosis of these patients. However, the
development of resistance and leukemia relapse, in particular
upon therapy discontinuation, still represents a major problem.
Thus, in recent years, a major research focus has been to
improve both DMR and TFR (8). Notably, a positive clinical
outcome in these patients appears to correlate with an efficient
immune response allowing the control of the CML residual
disease (13). Since NK cells are thought to play a relevant role
in this process, it was important to clarify whether TKI could
influence not only the repertoire and function of circulating
mature NK cells, but also their development from CD34+
HSC. To this end, we took advantage of an in vitro model
of NK cell differentiation from CD34+ cell precursors that
allows the generation of different ILC subsets. In addition, it
provides a useful tool to analyze factors/drugs that may modify
such process (27, 40). In the present experiments, CD34+
cells were cultured in the presence of Imatinib, Nilotinib, and
Dasatinib at plasmatic peak concentrations, to reproduce drug
concentrations present in PB and BM of TKI-treated patients.
An inhibitory effect of TKI on precursor cell proliferation
could be expected, since these compounds are known to
interfere with the SCF/c-KIT (CD117) transduction pathway that
plays a key role in the early steps of CD34+ cell activation
and proliferation (37, 41). However, the impairment of cell
proliferation and recovery was associated with an increase of
programmed cell death only in Dasatinib culture condition, in
which apoptosis was clearly detectable during the first week
of culture. Although all TKI analyzed induced a decrease of
CD161+CD56+ cell recovery, Dasatinib exerted a more marked
inhibitory effect. Moreover, only Dasatinib significantly skewed
the CD161+CD56+ cell repertoire favoring CD117+CD94−LFA-
1−-RORγt+ ILC3, while CD117−CD94+LFA-1+Eomes+ NK
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FIGURE 4 | Dasatinib increases the percentages of IL-22-producing CD56+CD117+CD94− and of IFN-γ-producing CD56+CD117+/−CD94+ cells while inhibits
cytolytic activity of CD56+ cells. After 25 days CD56+cells developed in the presence of Imatinib 5µM (IM), Nilotinib 3.6µM (NIL), Dasatinib 0.2µM (DAS) and DMSO
1:1000 (D 1:1000) were analyzed for the intra-cytoplasmic cytokine expression and for cell cytotoxicity. (A,B) CD56+ cells, developed in the absence or in the
presence of different TKI or DMSO 1:1000 were o.n. stimulated with IL-1β+IL-7+IL-23, to induce the production of IL-22 and TNF-α and IL-8 or with
IL-12+IL-15+IL-18, to favor the production of IFN-γ. Cells were analyzed for intra-cytoplasmic cytokine expression of IL-22, IL-8, IFN-γ, and TNF-α cytokines by flow
cytometry. (A) Flow cytometry analysis show representative experiment out of seven: dot plots represent the intra-cytoplasmic cytokine staining in
CD56+CD117+CD94/NKG2A− and CD56+CD117−/+ CD94/NKG2A+ cell subsets. (B) The histograms represent the fold change of IL-22, IL-8, IFN-γ, and TNF-α
positive cell percentages detected in CD56+CD117+CD94/NKG2A− and CD56+CD117−/+CD94/NKG2A+ cell subsets upon appropriate cytokine stimulation, as
compared to CTR, arbitrarily normalized to one. Data are expressed as mean percentage ± SEM of ten independent experiments and analyzed by Wilcoxon
signed-rank test (*p < 0.05). (C) The histogram shows the percentage cell lysis of human leukemic line K562 by CD161+CD56+ cells. Effector/target (E/T) cell ratio
was 2/1. Data are expressed as mean percentage ± SEM of four independent experiments and analyzed by Kruskal–Wallis multiple comparison test (*p < 0.05; **p <
0.005). (D) CD56+ cells were analyzed for intra-cytoplasmic expression of Perforin. Dot plots display Perforin intra-cytoplasmic staining in total CD56+ gated cells
and in CD56+LFA-1+(CD94+) gated cells. Representative experiment out of four performed.
cells were sharply reduced. The effect of Dasatinib on ILC
commitment was detectable at early stages, since analysis
performed at day 6 of culture revealed an increase of
CD117+CD127+CD132+ cells, representing ILC precursors,
while CD122 expression was undetectable. Previous studies on
factors that may influence human ILC in vitro development,
have shown that the presence of SCF is required to favor the
in vitro differentiation of ILC3 in the presence of IL-7 or IL-
15, while IL-15 and IL-7, alone or in combination with other
pro-inflammatory cytokines, skew precursor cell differentiation
toward NK cells (40, 42).
The SCF/c-kit transduction pathway involves STAT3 protein
phosphorylation, IL-15 pathway preferentially uses STAT5
signaling protein, while IL-7 can exploit both (37, 43). It has
been shown that Dasatinib inhibits the STAT3 and STAT5
signaling pathways through the inhibition of Src kinases, leading
to a durable inhibition of STAT5 phosphorylation, but only a
transient inhibition of STAT3 phosphorylation in CD34+ cells
isolated from CML patients at diagnosis (39). Our analysis
of STAT3/STAT5 phosphorylation in CD34+HSC revealed a
higher and durable reduction of pSTAT5+ cells as compared
to pSTAT3+ cells upon cell culture with Dasatinib during first
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FIGURE 5 | KX2-391 Src kinases inhibitor favors the development of CD56+CD117+RORγt+ cells, while inhibits generation and cytotoxicity of
CD56+CD94/NKG2A+EOMES+ cells. UCB-CD34+ cells were purified and cultured with cytokine-mix medium in the absence (control=CTR) or in the presence of
KX2-391 src kinase-inhibitor at different concentrations (5, 50, 100 nM) or Dasatinib at the plasma peak concentration (200 nM). (A) The histogram represents the
absolute cell numbers obtained after 15 days of culture, in the presence of KX2-391 inhibitor at different concentrations and Dasatinib, as compared to control,
arbitrarily normalized to one. The data are represented as mean±SEM obtained by nine independent experiments and analyzed by Wilcoxon signed-rank test (*p <
0.05; **p < 0.005). (B) Dot plots show the morphological features and Annexin V/PI staining observed in the cell precursors undergoing in vitro NK cell differentiation
in the presence of different culturing conditions: control (CTR), KX2-391 at different concentrations and Dasatinib. The cells were undergone to immunofluorescence
tests after 8 days of culture. (C) The histogram shows the fold change of CD161+CD56+ absolute cell number recovered after 15 days of culture in the presence of
KX2-391 inhibitor at different concentrations and Dasatinib, as compared to control, arbitrarily normalized to one. The data are represented as mean ±SEM obtained
by nine independent experiments and analyzed by Wilcoxon signed-rank test (*p < 0.05). (D) Box and Whiskers plots represent the fold change of CD56+RORγt+,
CD56+CD117+, CD56+EOMES+ and CD56+CD94/NKG2A+ cells, obtained after 25 days of culture in presence of KX2-391 5nM, as compared to control. The
data are obtained by seven independent experiments and analyzed by Wilcoxon signed-rank test (*p < 0.05). (E) Dot plots show analysis of CD94/NKG2A, RORγt
and EOMES TF in CD56+ cells, in the absence (= CTR) or in the presence of KX2-391 5 nM or Dasatinib 200 nM. Representative experiment out of three. (F) The
histogram represents the percentage cell lysis of human leukemic line K562 by CD161+CD56+ cells, after 27 days of culture, in the presence of KX2-391 5 nM and
Dasatinib 200 nM, as compared to control. Representative experiment out of two performed.
days of culture. Thus, it is conceivable that the early expression
of CD117 and CD127 on Dasatinib-treated cells may favor
the SCF/CD117- and IL-7/CD127–mediated STAT3 transduction
triggering pathway, thus favoring ILC precursors proliferation
and survival.
Functional analyses indicate that Dasatinib does not affect
cytokine production by ILC3 but rather induces increases of the
percentages of CD56+ CD117+RORγt+IL-22 producing cells.
Interestingly, the few NK cells, undergoing differentiation in
the presence of Dasatinib, contained higher percentages of IFN-
γ+cells. We also detected a slight increase of IL-8+/IFN-γ+ILC3
undergoing differentiation in the presence of Dasatinib. It has
been reported that lymphocyte mobilization in Dasatinib-treated
patients is frequently associated with adverse effects such as
pleural effusion, autoimmune-like syndromes and colitis (29).
Of note, ILC3 are thought to play a relevant role in intestinal
inflammation (25). In addition, they may exacerbate intestinal
inflammation due to their ability to differentiate toward IFN-
γ-producing ILC1 cells upon IL-12 stimulation (44). Thus, the
inflammatory side effects induced byDasatinib inmucosal tissues
may reflect, at least in part, increases in the production of IL-22,
IL-8, and IFN-γ by ILC. Of note, the increase of IFN-γ-expressing
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FIGURE 6 | Analysis of the Dasatinib-mediated effect on STAT3 and STAT5 phosphorylation in CD34+ cells undergoing differentiation toward CD56+cells at different
culture time intervals. (A) UCB-CD34+ cells were isolated and cultured with cytokine-mix medium, in the absence or in the presence of Dasatinib 200 nM for 18, 24,
and 48 h. Cells were analyzed for the expression of pSTAT3 and pSTAT5 signaling proteins. The histograms show the fold changes of CD34+pSTAT3+ and
CD34+pSTAT5+ positive cell percentages detected in the presence of Dasatinib, as compared to control, arbitrarily normalized to one. Data are expressed as mean
values ± SEM obtained by four independent experiments. (B) UCB-CD34+ cells were isolated and cultured with cytokine-mix medium, in the absence or in the
presence of Dasatinib 200 nM for 72 h. Flow cytometry analyses show the intra-cytoplasmic expression of pSTAT3 and pSTAT5 on total cell population and on
CD14−CD117+ gated cells. (C) CD56+ cells obtained from UCB-CD34+ cells after 20 days of culture, in the absence (CTR) or in the presence of Dasatinib 200 nM
were analyzed for the expression of pSTAT3 and pSTAT5 signaling proteins. The histogram shows the fold change of CD56+pSTAT3+ and CD56+pSTAT5+ cell
percentages detected in the presence of Dasatinib, as compared to control, arbitrarily normalized to one. Data are expressed as mean values ± SEM obtained by four
independent experiments.
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FIGURE 7 | Schematic representation of potential effects of Dasatinib on IL-7/IL-15 transduction pathways. IL-7 and IL-15 cytokines can signal both through the
JAK-STAT and the Src pathways.After 20 days of culture, in the control condition, the cytokine receptors engagement by IL-7 and IL-15 leads both to JAK- and Src-
STAT-mediated recruitment and phosphorylation. In the presence of Dasatinib, Src-mediated STAT phosphorylation pathway is abrogated, while cytokine-driven
JAK-activation pathway would provide compensatory signals, allowing STAT5 phosphorylation.
CD56+ cells detectable after 25 days of culture in the presence
of Dasatinib, paralleled the increase of CD56+pSTAT5+cell
percentages. These data may suggest that a prolonged exposure
to IL-7 and IL-15 may provide compensatory signals, allowing
lymphoid cell cytokine production even in the presence of a
chronic exposure to Dasatinib (45) (Figure 7).
The cytolytic activity of CD56+ NK cells developed in the
presence of Dasatinib was impaired. It is conceivable that the
reduction of cytotoxicity may reflect the lower number of mature
NK cells however, we could also detect a decrease of Perforin
content in the few mature NK cells present in Dasatinib cultures.
In addition, it should be considered the inhibitory effect exerted
by Dasatinib on Src kinases and on ERK protein phosphorylation
(p-ERK), required for the cytolytic degranulation process (39,
46, 47). Indeed, our experiments using KX2-391 inhibitor would
confirm that the effect on the CD56+ cell repertoire induced
by Dasatinib, may be due to the impairment of Src kinase
pathway. Notably, KX2-391 induced massive cell apoptosis at
the concentration of 200 nM while at lower concentrations
the proportions of Annexin V+ cells were low. However, the
use of KX2-391 at lower concentrations skewed the CD56+
cell repertoire toward CD56+CD117+CD94/NKG2A− RORγt+
ILC3, similar to what detected in cultures performed in the
presence of Dasatinib.
Studies in mice models have suggested that IL-15/STAT5
pathway may represent a central node in NK cell homeostasis
and in the TF network that instructs ILC development (48–
51). Our data indicate that exposure to Src kinase inhibitors
may play a relevant a role in the inhibition of human NK
cell development and in the acquisition of cytolytic activity,
while the cytokine-driven STAT3 and STAT5 activation pathway
may overcome Dasatinib-mediated inhibition and favor the
preferential survival of CD117+ CD127+ ILC3 precursors and
the subsequent cytokine production by both mature ILC3 and
NK cells detectable at later time culture intervals.
It has been reported that Dasatinib, may induce cytotoxic
CD56+CD57+ NK cell mobilization in the PB and BM of TKI-
treated patients (29–31, 52). It is conceivable that different
effects detectable in vitro vs. in vivo of Dasatinib-treatment
may be consequent to the short half-life of the drug in plasma
vs. its stable levels in cell cultures (53). Notably, it has been
suggested that the incidence of lymphocytosis does not correlate
with DMR, while the numbers and percentages of circulating
cytotoxic NK cells and CTL were significantly higher in patients
with DMR as compared to those with no DMR (30). The
high degree of heterogeneity of cases analyzed may contribute
to the variability of responses: patients may undergo different
TKI administration protocols, and the immune system status
(immunosuppression, viral reactivation, therapy-related BM/
lymphoid organs exhaustion) may greatly influence immune cell
repertoire and function, having an impact on the clinical outcome
of CML-treated patients (13).
Frontiers in Immunology | www.frontiersin.org 11 October 2018 | Volume 9 | Article 2433
Damele et al. Dasatinib Impairs NK Cell Development
In conclusion, our results suggest that Dasatinib may
affect NK cell development, and offer new clues to better
understand the signaling pathways that regulate development
and proliferation of precursors toward NK cells and other
ILC. The Dasatinib-induced skewing of ILC differentiation
toward ILC3 and increasing of IFN-γ producing cells should be
considered in patients with severe therapy-induced side effects
or with limited responses to therapy. Moreover, in Dasatinib-
treated patients, it will be important to better characterize both
the lymphoid cell precursors and the mature cytolytic effector
cells present in patients BM, i.e., the site where drug-resistant
leukemic clones primarily reside (54). Finally, our study, could
offer a clue for identifying new tools to design individualized
timing and dosing of Dasatinib administration in order to obtain
optimal responses without compromising the NK cell-based
immunotherapeutic intervention.
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